WO2024025173A1 - Cosmetic composition comprising staphylococcus sp. strain, streptococcus sp. strain, cutibacterium sp. strain, enhydrobacter sp. strain, and dna fragment mixture - Google Patents

Cosmetic composition comprising staphylococcus sp. strain, streptococcus sp. strain, cutibacterium sp. strain, enhydrobacter sp. strain, and dna fragment mixture Download PDF

Info

Publication number
WO2024025173A1
WO2024025173A1 PCT/KR2023/009049 KR2023009049W WO2024025173A1 WO 2024025173 A1 WO2024025173 A1 WO 2024025173A1 KR 2023009049 W KR2023009049 W KR 2023009049W WO 2024025173 A1 WO2024025173 A1 WO 2024025173A1
Authority
WO
WIPO (PCT)
Prior art keywords
strain
culture medium
culture
lysate
extract
Prior art date
Application number
PCT/KR2023/009049
Other languages
French (fr)
Korean (ko)
Inventor
조형우
이동걸
강승현
백승걸
강소민
Original Assignee
코스맥스 주식회사
주식회사 파마리서치
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코스맥스 주식회사, 주식회사 파마리서치 filed Critical 코스맥스 주식회사
Publication of WO2024025173A1 publication Critical patent/WO2024025173A1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin

Definitions

  • Microorganisms living on human skin are known to maintain a symbiotic relationship with their human hosts and have various effects on skin aging by interacting with humans. These microorganisms and various information, including their genes, are called skin microbiome.
  • NGS next generation sequencing
  • Human skin which is the habitat of these microorganisms, comes in contact with the external environment and serves as a collection site for various microorganisms (e.g., fungi, bacteria, viruses, and small larvae).
  • various microorganisms e.g., fungi, bacteria, viruses, and small larvae.
  • the microorganisms prepare a habitat by adapting according to the selection of physical and chemical functions.
  • the epidermis forms the skin barrier and plays an important role in blocking the penetration of microorganisms and toxins and maintaining moisture.
  • the uppermost layer of the epidermis is composed of the stratum corneum.
  • the epidermis has a form called a ‘brick and mortar structure’. Skin tissue goes through a continuous self-recovery process, and scales that have completed the differentiation process constantly repeat the process of being shed from the skin tissue. It has been revealed that microorganisms influence these changes in the skin.
  • MMPs matrix metalloproteinases
  • photoaging is considered the biggest aging factor of the skin, and accordingly, many products to prevent photoaging are being released.
  • photoaging prevention technology using natural materials is limited in use and various problems arise when verifying efficacy. There are limitations in many cases.
  • One aspect is a Staphylococcus sp. strain, its lysate, culture, extract of the culture, or a mixture thereof; Streptococcus sp. strain, its lysate, culture, extract of the culture, or mixtures thereof; Cutibacterium sp. strain, its lysate, culture, extract of the culture, or mixtures thereof; Enhydrobacter sp. strain, its lysate, culture medium, extract of the culture medium, or mixtures thereof; and a composition for improving skin condition comprising a DNA fragment mixture as an active ingredient.
  • Another aspect provides a method of preventing, ameliorating, or treating a condition in a subject comprising treating or administering an effective amount of the composition described above to the subject in need thereof.
  • Another aspect includes the above-mentioned four strains, their lysate, culture medium, extract of the culture medium, or mixtures thereof for use in preparing a composition for improving skin condition; and the use of DNA fragment mixtures.
  • One aspect is a Staphylococcus sp. strain, its lysate, culture, extract of the culture, or a mixture thereof; Streptococcus sp. strain, its lysate, culture, extract of the culture, or mixtures thereof; Cutibacterium sp. strain, its lysate, culture, extract of the culture, or mixtures thereof; Enhydrobacter sp. strain, its lysate, culture medium, extract of the culture medium, or mixtures thereof; and a DNA fragment mixture as an active ingredient.
  • lysate may be used interchangeably with “lysate” and may refer to a product obtained by breaking the cell wall of a strain by chemical or physical force.
  • the lysate may include the lysate itself, its concentrate, or its freeze-dried product.
  • the term “culture” may be used interchangeably with “culture supernatant,” “conditioned culture,” or “conditioned medium,” and may be used interchangeably with the genus Staphylococcus, Streptococcus, Cutibacterium, and/or Inhydro. It may refer to the entire medium containing the strain, its metabolites, extra nutrients, etc. obtained by culturing the strain for a certain period of time in a medium that can supply nutrients so that the Bacter strain can grow and survive in vitro. Additionally, the culture medium may refer to a culture medium obtained by removing the bacterial cells from the bacterial culture medium obtained by culturing the strain.
  • the liquid from which the bacteria have been removed from the culture medium is also called “supernatant", and the supernatant is obtained by leaving the culture solution still for a certain period of time and taking only the upper liquid excluding the part that has settled in the lower layer, or by removing the bacteria through filtration, or by removing the culture liquid. It can be obtained by centrifuging to remove the sediment at the bottom and taking only the liquid at the top.
  • the "bacteria” refers to the strain itself of the present invention, and includes the strain itself separated and selected from a sample, etc., or a strain isolated from the culture medium by culturing the strain.
  • the bacterial cells can be obtained by centrifuging the culture medium and taking the part that has sunk to the lower layer. Alternatively, since they sink to the lower layer of the culture medium by gravity, they can be obtained by leaving them still for a certain period of time and then removing the upper liquid.
  • the culture medium includes strains of the genus Staphylococcus, Streptococcus, Cutibacterium, and/or Inhydrobacter in a medium (e.g., R2A, TSB, TSA, BHI or RCM medium) at an appropriate temperature (e.g. : It may be obtained by culturing for a certain period of time (e.g., 4 to 120 hours) at any temperature above 10°C or below 40°C.
  • a medium e.g., R2A, TSB, TSA, BHI or RCM medium
  • an appropriate temperature e.g. : It may be obtained by culturing for a certain period of time (e.g., 4 to 120 hours) at any temperature above 10°C or below 40°C.
  • the culture medium may include the culture medium itself, its concentrate, or freeze-dried product obtained by cultivating the strain, or the culture supernatant obtained by removing the strain from the culture medium, its concentrate, or freeze-dried product.
  • the culture supernatant of the strain may be obtained by removing the strain by centrifuging or filtering the strain culture fluid.
  • the concentrate may be obtained by concentrating the strain culture itself or the supernatant obtained after centrifuging or filtering the culture.
  • culture extract refers to an extract from the culture medium or its concentrate, and may include extracts, diluted or concentrated extracts, dried products obtained by drying the extracts, crude or purified products thereof, and fractions thereof. You can.
  • the strain, its lysate, culture medium, or extract of the culture medium may be biologically pure.
  • the strain may be obtained by pure culture.
  • a mixture of strains and DNA fragments of the genus Staphylococcus, Streptococcus, Cutibacterium, and Inhydrobacter increase the expression of genetic markers COL1A1 and elastin (ELN), which are reduced by ultraviolet rays, and increase the expression of genes related to skin moisturization. It was confirmed that the expression of factors (eg, HAS3) and skin barrier-related factors (eg, ABCA12) was increased. Therefore, the composition can be used to improve skin condition, improve skin beauty, prevent, improve or treat skin diseases, etc.
  • factors eg, HAS3
  • skin barrier-related factors eg, ABCA12
  • the improvement of skin condition or skin beauty may be preventing skin aging (anti-aging), improving skin wrinkles (anti-wrinkle), improving skin elasticity, moisturizing skin, or strengthening the skin barrier.
  • skin aging refers to both tangible and intangible changes that occur in the skin as one ages. Skin aging includes, for example, a thinning of the epidermis, a decrease in the number of cells or blood vessels in the dermis, a decrease in the ability to repair DNA damage, an increase in the cell turnover cycle, a decrease in the ability to heal wounds, a weakening of the skin barrier function, a decrease in the moisture retention ability of the epidermis, These include reduced sweat secretion, reduced sebum secretion, reduced vitamin D production, reduced ability to defend against physical damage, reduced ability to eliminate chemicals, reduced immune response, weakened sensory function, and reduced body temperature regulation.
  • the prevention of skin aging may mean improving skin aging caused by extrinsic or endogenous factors.
  • the exogenous factors refer to various external factors, such as ultraviolet rays (light).
  • the endogenous factors are also referred to as chronological factors and mainly refer to factors that occur due to the passage of time.
  • the skin aging is specifically not only a symptom of premature aging induced by external stimuli such as ultraviolet rays, pollution, cigarette smoke, chemicals, etc., but also a natural aging phenomenon that occurs as the proliferation of skin cells decreases with age. It is a concept that includes wrinkles, loss of elasticity, skin sagging and dryness, etc.
  • wrinkles include stimulation caused by changes in internal and external factors that change the components that make up skin tissue, causing wrinkles.
  • the aging may be photoaging.
  • photoaging is a phenomenon caused by external environmental factors, the most representative factor being ultraviolet rays. Ultraviolet rays cause damage to biological components such as activation of proteolytic enzymes, chain cutting of matrix proteins, and abnormal cross-linking, and repetition of this mechanism causes skin aging that is evident in appearance.
  • wrinkle refers to a state in which the skin loses its elasticity and becomes loose, for example, the skin may be folded.
  • prevention or improvement of skin wrinkles may refer to any action that prevents or improves wrinkles by suppressing the expression of factors related to wrinkles, or increases the total amount of collagen.
  • skin moisturizing may refer to any action that maintains skin moisture or prevents moisture loss.
  • skin barrier strengthening may refer to any action that improves the function of the skin barrier, which is located on the outermost layer of the skin and prevents moisture and nutrition loss.
  • the “skin disease” may be a disease caused by damage to the skin barrier function, skin aging, skin wound, skin scar, or skin inflammation.
  • prevention includes suppressing the occurrence of a disease.
  • treatment includes inhibiting, alleviating, or eliminating the development of a disease.
  • improvement may refer to any action that results in at least reducing the severity of a parameter associated with the alleviation or treatment of a condition, such as symptoms.
  • the damage to the skin barrier function may mean any change that appears in the skin due to decreased or damaged skin barrier function. For example, it may include increased skin wrinkles, dryness, dermatitis, atopic dermatitis, allergic dermatitis, acne, etc.
  • the Staphylococcus sp. strains include, for example, Staphylococcus epidermidis , Staphylococcus hominis , Staphylococcus warneri , Staphylococcus caprae , It may be Staphylococcus capitis , etc.
  • the Staphylococcus genus strain may be Staphylococcus epidermidis (Accession Number: KCCM12559P).
  • the Staphylococcus genus strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof may be included in an amount of 5 to 20% by weight based on the total weight of the composition.
  • the Staphylococcus genus strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof is, for example, 5 to 20% by weight, 5 to 18% by weight, 5 to 16% by weight, 7 to 7% by weight, based on the total weight of the composition. It may be included at 20% by weight, 7 to 17% by weight, 8 to 15% by weight, or 10 to 13% by weight.
  • Streptococcus genus ( Streptococcus sp.) strains are, for example, Streptococcus thermophiles, Streptococcus mitis , Streptococcus infantis , It may be Streptococcus pneumoniae , etc.
  • the Streptococcus genus strain may be Streptococcus thermophiles (Accession number: KCCM12004P).
  • the Streptococcus genus strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof may be included in an amount of 5 to 30% by weight based on the total weight of the composition.
  • the Streptococcus genus strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof is contained in an amount of 5 to 30% by weight, 5 to 28% by weight, 5 to 25% by weight, 5 to 20% by weight, 8%, based on the total weight of the composition. It may be included in an amount of from 30% by weight, 8 to 24% by weight, 8 to 18% by weight, 10 to 27% by weight, 10 to 20% by weight, or 10 to 15% by weight.
  • the Cutibacterium sp. strain may be, for example, Cutibacterium acnes , Cutibacterium granulosum , etc.
  • the strain of the Cutibacterium genus may be Cutibacterium acnes (Accession Number: KCCM12680P).
  • the Cutibacterium genus strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof may be included in an amount of 50 to 90% by weight based on the total weight of the composition.
  • the Cutibacterium genus strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof is, for example, 50 to 90% by weight, 50 to 80% by weight, 50 to 70% by weight, 55 to 55% by weight, based on the weight of the species of the composition. It may be included at 90% by weight, 55 to 85% by weight, 55 to 75% by weight, 60 to 90% by weight, 60 to 80% by weight, or 70 to 75% by weight.
  • the Enhydrobacter sp. strain may be, for example, Enhydrobacter aerosaccus (Accession number: KCCM13073P).
  • the Inhydrobacter genus strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof may be included in an amount of 0.5 to 10% by weight based on the total weight of the composition.
  • the Inhydrobacter genus strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof is, for example, 0.5 to 10% by weight, 0.5 to 8% by weight, 0.5 to 5% by weight, 1 to 1% by weight, based on the total weight of the composition. It may be included at 7% by weight, 1 to 6% by weight, 2 to 9% by weight, or 2 to 5% by weight.
  • DNA fragment mixture is a form in which DNA corresponding to a biopolymer composed of phosphoric acid, four types of bases, and deoxyribose is extracted and exists in a mixture of DNA fragments having various molecular weights.
  • the DNA fragment mixture may be hydrolyzed.
  • the DNA fragment mixture may be, for example, polydeoxyribonucleotide (PDRN), polynucleotide, etc.
  • the polydeoxyribonucleotide (PDRN) is a mixture of short deoxyribonucleotides, a low molecular weight DNA complex made by fractionating DNA chains to a certain size. It's kind of like that.
  • the polynucleotide refers to a DNA or RNA strand of a certain length or more, which is a polymer of nucleotides in which nucleotide monomers are connected in a chain shape by covalent bonds.
  • the polynucleotide may have a relatively longer nucleic acid length or a higher molecular weight than a polydeoxyribonucleotide, but is not limited thereto.
  • the molecular weight of the DNA fragment mixture may be 50 to 10,000 kDa.
  • the molecular weight of the DNA fragment mixture may be, for example, 50 to 10,000 kDa, 50 to 5,000 kDa, 50 to 3,000 kDa, 50 to 1,500 kDa, 1,000 to 10,000 kDa, 1,000 to 5,000 kDa, or 5,000 to 10,000 kDa.
  • the DNA fragment mixture may be a mixture of DNA fragments obtained by extraction from testes or semen of a fish, and the fish may be a salmonid, specifically salmon or trout.
  • the DNA fragment mixture may be included in an amount of 0.01 to 1% by weight based on the total weight of the composition.
  • the DNA fragment mixture may be included, for example, at 0.01 to 1% by weight, 0.01 to 0.7% by weight, 0.03 to 0.7% by weight, 0.1 to 0.8% by weight, or 0.3 to 0.6% by weight, based on the total weight of the composition. At this time, if the content of the DNA fragment mixture is less than or exceeds the above range, there is a problem that the skin condition improvement effect cannot be sufficiently exhibited.
  • the composition may have synergistic activity in improving skin condition by containing strains of the genus Staphylococcus, Streptococcus, Cutibacterium, and Inhydrobacter and a mixture of DNA fragments in a specific weight ratio.
  • the mixture of strains and DNA fragments of the Staphylococcus genus, Streptococcus genus, Cutibacterium genus, and Inhydrobacter genus is, for example, 1:1 to 2:5 to 7:0.1 to 0.5:0.01 to 0.06, 1:1 It may be mixed at a weight ratio of 1.5:5 to 6.5:0.1 to 0.3:0.01 to 0.05, or 1:1 to 1.3:5.5 to 7:0.2 to 0.5:0.03 to 0.05.
  • the composition according to one aspect includes a Staphylococcus sp. strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof; Streptococcus sp. strain, its lysate, culture, extract of the culture, or mixtures thereof; Cutibacterium sp. strain, its lysate, culture, extract of the culture, or mixtures thereof; Enhydrobacter sp. strain, its lysate, culture medium, extract of the culture medium, or mixtures thereof; and a DNA fragment mixture in a specific content and weight ratio can exert a synergistic effect in improving skin condition.
  • the term "included as an active ingredient” refers to the strain of the present specification, its lysate, culture medium, or extract of the culture medium to the extent that it can exhibit the above-mentioned effects; and/or DNA fragment mixture is added, and includes formulation in various forms by adding various ingredients as sub-ingredients for drug delivery and stabilization.
  • the composition may be a cosmetic composition.
  • the cosmetic composition may further include ingredients commonly used in cosmetic compositions, functional additives, etc., such as antioxidants, stabilizers, solubilizers, surfactants, dispersants, emulsifiers, and preservatives. , conventional auxiliaries such as vitamins, pigments, fragrances, etc., and carriers.
  • the cosmetic composition is not particularly limited to a specific formulation, and the formulation may be appropriately selected depending on the purpose.
  • the cosmetic composition may have, for example, a solubilized formulation, an emulsified formulation, or a dispersed formulation.
  • the cosmetic composition includes, for example, lotion, cream, essence, cleansing foam, cleansing water, pack, ampoule, body lotion, body oil, body gel, shampoo, rinse, hair conditioner, hair gel, foundation, lipstick, mascara, and makeup. It may have a base or skin-adhesive cosmetic formulation.
  • the skin-adhesive cosmetic formulation may be, for example, a mask pack, but is not limited thereto.
  • the composition may be a composition for external application to the skin.
  • the external skin preparation may be a cream, gel, ointment, skin emulsifier, skin suspension, transdermal delivery patch, drug-containing bandage, lotion, or a combination thereof.
  • the skin external preparations include ingredients commonly used in external skin preparations such as cosmetics and medicines, such as aqueous ingredients, oil-based ingredients, powder ingredients, alcohols, moisturizers, thickeners, ultraviolet absorbers, whitening agents, preservatives, antioxidants, surfactants, and fragrances. , colorants, various skin nutrients, metal ion sequestrants, sugars, or combinations thereof may be appropriately mixed as needed.
  • the composition may be a health functional food composition.
  • the health functional food composition may be used alone or in combination with other foods or food ingredients, and may be used appropriately according to conventional methods.
  • the mixing amount of the active ingredient can be appropriately determined depending on the purpose of use (prevention, health, or therapeutic treatment).
  • the composition of the present specification may be added in an amount of 15 parts by weight or less based on the raw materials.
  • beverage compositions may contain various flavoring agents or natural carbohydrates as additional ingredients like ordinary beverages.
  • the natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; and polysaccharides such as dextrins and cyclodextrins; Sugar alcohols such as xylitol, sorbitol, and erythritol.
  • a sweetener natural sweeteners such as thaumatin and stevia extract or synthetic sweeteners such as saccharin and aspartame can be used.
  • the health food composition also contains nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, and carbonated beverages. It may contain the carbonating agent used, or a combination thereof.
  • the health functional food composition may also contain pulp for the production of natural fruit juice, fruit juice beverage, vegetable beverage, or a combination thereof.
  • Another aspect provides a method of preventing, ameliorating, or treating a condition in a subject comprising treating or administering an effective amount of the composition described above to the subject in need thereof.
  • the condition of the subject may be a condition related to skin-related conditions, and specifically, may be a disease caused by damage to the skin barrier function or skin aging.
  • administering As used herein, the terms “administering,” “introducing,” and “implanting” are used interchangeably and refer to an individual by a method or route that results in at least partial localization of the composition according to one embodiment to the desired site. It may refer to the arrangement of the composition according to one embodiment into the inner space.
  • Administration may be by methods known in the art.
  • the administration method such as administration route and administration frequency, can be appropriately selected by a person skilled in the art.
  • Administration may be administered directly to the subject by any means, such as, for example, intravenous, intramuscular, oral, transdermal, mucosal, intranasal, intratracheal or subcutaneous administration. You can.
  • the administration may be administered systemically or locally.
  • the administration may include application to the skin.
  • the subject may be a mammal, such as a human, cow, horse, pig, dog, sheep, goat, or cat.
  • the subject may be an entity that requires improvement of skin condition, for example, an entity that requires anti-aging skin, improvement of skin wrinkles, enhancement of skin elasticity, skin moisturization, strengthening of skin barrier, and inhibition of skin inflammation.
  • the administration of the composition according to one embodiment is 0.1 mg to 1,000 mg, for example, 0.1 mg to 500 mg, 0.1 mg to 100 mg, 0.1 mg to 50 mg, 0.1 mg to 25 mg, 1 mg to 1 mg per day.
  • the dosage may be prescribed in various ways depending on factors such as formulation method, administration method, patient's age, weight, gender, pathological condition, food, administration time, administration route, excretion rate, and reaction sensitivity, and those skilled in the art will Taking these factors into consideration, the dosage can be adjusted appropriately.
  • the frequency of administration can be once a day or two or more times within the range of clinically acceptable side effects.
  • the administration site it can be administered at one or two or more locations, and the total number of administration days can be from 1 to 30 days for one treatment, either daily or at intervals of 2 to 5 days. If necessary, the same treatment can be repeated after an appropriate period.
  • the dosage per kg is the same as for humans, or the above dosage is converted into, for example, the volume ratio (e.g., average value) of the organs (heart, etc.) between the target animal and human.
  • One dose can be administered.
  • Another aspect includes the above-mentioned four strains, their lysate, culture medium, extract of the culture medium, or mixtures thereof for use in preparing a composition for improving skin condition; and uses of DNA fragment mixtures.
  • Redundant content is omitted in consideration of the complexity of the present specification, and terms not otherwise defined in the present specification have meanings commonly used in the technical field to which the present invention pertains.
  • composition according to one aspect increases the expression of collagen, elastin, HAS3, and ABCA12, and can be usefully used to improve skin conditions such as skin aging, skin moisturizing, skin barrier strengthening, skin wrinkles, or skin elasticity.
  • Figure 1 is a result showing the effect of a composition according to one aspect on COL1A1 expression.
  • Figure 2 is a result showing the effect of a composition according to one aspect on ELN expression.
  • Figure 3 is a result showing the effect of a composition according to one aspect on HAS3 expression.
  • Figure 4 is a result showing the effect of a composition according to one aspect on ABCA12 expression.
  • Staphylococcus epidermidis strain culture medium was prepared. Specifically, Staphylococcus epidermidis strain (Accession number: KCCM12559P) was received from the Korean Culture Center of Microorganisms (KCCM) and grown at 150 rpm/min in R2A (Reasoner's 2A) medium. It was suspended and cultured for enrichment. The temperature was maintained at about 30°C during the culturing period, and after culturing for 72 hours, the culture medium was filtered using a 0.45 ⁇ m filter.
  • Staphylococcus epidermidis strain accesion number: KCCM12559P
  • R2A Reasoner's 2A
  • Streptococcus thermophiles strain (Accession number: KCCM12004P) and TSB (Tryptic Soy Broth) medium were used, except that Streptococcus thermophiles strain culture medium was prepared in the same manner as in Preparation Example 1 . did.
  • Cutibacterium acnes strain (Accession number: KCCM12680P) was prepared in the same manner as in Preparation Example 1 except that it was stationary cultured using RCM (Reinforced Clostridial Medium) medium. Culture medium was prepared.
  • An Enhydrobacter aerosaccus strain culture medium was prepared in the same manner as in Preparation Example 3, except that the Enhydrobacter aerosaccus strain (accession number: KCCM13073P) was used.
  • Example 1 Preparation of a composition comprising strain culture medium and DNA fragment mixture
  • a composition containing the ingredients and contents shown in Table 1 below was prepared. Specifically, a composition was prepared by mixing the culture media of Preparation Examples 1 to 4 with hydrolyzed DNA (manufactured by Pharma Research Co., Ltd.) with a molecular weight of 50 to 1,500 kDa.
  • the hydrolyzed DNA is a mixture of DNA fragments in a white or off-white powder. Unless otherwise stated herein, content is in weight percent.
  • composition was prepared in the same manner as Example 1, except that it included the ingredients and contents shown in Table 2 below.
  • Comparative Example 1 has the same mixing ratio of the strain culture medium as Example 1, but differs in that it contains sterilized distilled water instead of hydrolyzed DNA.
  • composition was prepared in the same manner as Example 1, except that it included the ingredients and contents shown in Table 3 below.
  • Comparative Example 2 differs from Example 1 in the mixing ratio of the strain culture medium.
  • the skin aging, wrinkle improvement, and skin elasticity enhancing activities of the composition according to one aspect were confirmed.
  • Human dermal fibroblast (Hs68) cell line was distributed at 3.5x10 5 in a 6-well plate and cultured in an incubator at 37°C and 5% CO 2 for 24 hours. Afterwards, the medium was removed, DPBS (Dulbecco's phosphate-buffered saline) was added, and 20 mJ/cm 2 UVB was irradiated or not. Immediately after UVB irradiation, DPBS was removed and replaced with medium without FBS fetal bovin serum, and then treated with the composition prepared in the above Examples and Comparative Examples and further cultured for 24 hours. As a negative control group, a group untreated with ultraviolet rays and strain culture was used.
  • DPBS Dens phosphate-buffered saline
  • cDNA was synthesized (C1000 Thermal Cycler, Bio-Rad, USA). Using the synthesized cDNA as a template, Cybergreen (SYBR Green supermix, Applied Biosystems, USA) and primers (primers for COL1A1 or primers for ELN) were added to a real-time PCR machine (Step One Plus, AppliedBiosystems, USA). Real-time polymerase chain reaction was performed. The expression level of the gene was finally analyzed through correction for the ⁇ -actin gene.
  • Figure 1 is a result showing the effect of a composition according to one aspect on COL1A1 expression.
  • Figure 2 is a result showing the effect of a composition according to one aspect on ELN expression.
  • composition according to one aspect increases the expression of COL1A1 and elastin, which are reduced by ultraviolet rays, by including four types of strain cultures and a mixture of DNA fragments as active ingredients, thereby preventing skin aging (e.g. photoaging) (anti-aging) ), is effective in improving wrinkles (anti-wrinkle) and improving skin elasticity.
  • skin aging e.g. photoaging
  • anti-aging anti-aging
  • the skin moisturizing activity of the composition according to one aspect was confirmed.
  • HaCaT cells a human keratinocyte cell line, were cultured in DMEM medium (Dulbecco's modified Eagle's Medium, Gibco 1210-0038) containing 10% fetal bovine serum, and all cultures were performed at 37°C and 5% CO 2 It was performed in an incubator.
  • the cultured cell lines were treated with the compositions prepared in the Examples and Comparative Examples and further cultured for 24 hours.
  • HAS3 gene expression level was analyzed using the same method as Experimental Example 1-2, except that primers for HAS3 (hyaluronic acid synthase) were used.
  • Figure 3 is a result showing the effect of a composition according to one aspect on HAS3 expression.
  • composition according to one aspect significantly increases the expression of HAS3 by including four types of strain cultures and a mixture of DNA fragments as active ingredients, and can be usefully used to improve skin moisturization.
  • the skin barrier function improvement activity of the composition according to one aspect was confirmed.
  • HaCaT cells a human keratinocyte cell line, were treated with polyIC (polyinosinic:polycytidylic acid; Poly I:C), a synthetic ribonucleic acid that promotes interferon production, and then cultured for 24 hours to stimulate the HaCaT cell line. Thereafter, cells aged by stimulation were treated with 1% (w/w) of the composition prepared in the above Examples and Comparative Examples and further cultured for 24 hours.
  • polyIC polyinosinic:polycytidylic acid
  • Poly I:C polyinosinic:polycytidylic acid
  • a synthetic ribonucleic acid that promotes interferon production
  • ABCA12 ATP-binding cassette sub-family A member 12
  • Figure 4 is a result showing the effect of a composition according to one aspect on ABCA12 expression.
  • composition according to one aspect significantly increases the expression of ABCA12 by including four types of strain cultures and a mixture of DNA fragments as active ingredients, and can be usefully used to improve the skin barrier.
  • the composition according to one aspect includes a mixture of four types of strain cultures and DNA fragments, thereby (i) increasing the expression of COL1A1 and ELN reduced by ultraviolet rays, (ii) increasing the expression of HAS3 effect, (iii) has the effect of increasing the expression of ABCA12.
  • the effects of (i) to (iii) were significantly better than those of Comparative Example 1, which did not contain a mixture of DNA fragments, or Comparative Example 2, which had a different mixing ratio of the strain culture medium.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)

Abstract

The present invention relates to a cosmetic composition comprising a Staphylococcus sp. strain, a Streptococcus sp. strain, a Cutibacterium sp. strain, a culture broth of an Enhydrobacter sp. strain, and a DNA fragment mixture. The composition can be effectively used in the prevention, amelioration or treatment of skin-related conditions.

Description

스타필로코커스 속, 스트렙토코커스 속, 쿠티박테리움 속, 인하이드로박터 속 균주 및 DNA 단편 혼합물을 포함하는 화장료 조성물A cosmetic composition comprising a mixture of Staphylococcus genus, Streptococcus genus, Cutibacterium genus, and Inhydrobacter genus strains and DNA fragments
화장료 조성물에 관한 것이다.It relates to cosmetic compositions.
인간의 피부에서 거주하고 있는 미생물은 숙주인 인간과 공생관계를 유지하며 인간과 상호작용을 함으로써 피부 노화에 다양한 영향을 미친다고 알려져 있다. 이러한 미생물 및 이들이 가진 유전자를 비롯한 다양한 정보를 스킨 마이크로바이옴(skin microbiome)이라고 한다. 최근 차세대 염기서열 분석 기술(Next generation sequencing, NGS)이 발달함에 따라, 마이크로바이옴을 분석하는 방법을 쉽게 활용할 수 있게 되었으며, 환경 내에 존재하는 균주의 전반적인 분포에 대한 분석이 가능하게 되었다. Microorganisms living on human skin are known to maintain a symbiotic relationship with their human hosts and have various effects on skin aging by interacting with humans. These microorganisms and various information, including their genes, are called skin microbiome. With the recent development of next generation sequencing (NGS), methods for analyzing the microbiome have become easily available, and analysis of the overall distribution of strains existing in the environment has become possible.
상기 미생물의 서식지인 인간의 피부는 외부 환경과 접촉하며 다양한 미생물(예: 진균, 세균, 바이러스 및 작은 유충)의 집합소 역할을 한다. 또한, 상기 미생물은 물리적, 화학적 기능의 선택에 따라 적응함으로써 서식처를 마련한다. Human skin, which is the habitat of these microorganisms, comes in contact with the external environment and serves as a collection site for various microorganisms (e.g., fungi, bacteria, viruses, and small larvae). In addition, the microorganisms prepare a habitat by adapting according to the selection of physical and chemical functions.
한편, 피부의 표면은 차갑고, 약산성의 성질을 나타내며, 건조한 상태로 유지된다. 구조적으로 표피(epidermis)는 피부 장벽을 이루고 있으며, 미생물과 독소가 침투하는 것을 차단하고, 수분을 유지하는 중요한 역할을 한다. 표피의 최상위층은 각질층(stratum corneum)으로 구성되어 있다. 표피는 일명 '벽돌과 몰탈 구조'라고 불리는 형태를 띠고 있다. 피부 조직은 계속적인 자가 회복 과정을 거치고, 분화과정의 마지막을 거친 비늘(squames)은 끊임없이 피부조직에서 탈락되는 과정을 반복하게 되는데, 이러한 피부의 변화에는 미생물이 영향을 준다는 것들이 밝혀지고 있다.Meanwhile, the surface of the skin is cold, shows slightly acidic properties, and remains dry. Structurally, the epidermis forms the skin barrier and plays an important role in blocking the penetration of microorganisms and toxins and maintaining moisture. The uppermost layer of the epidermis is composed of the stratum corneum. The epidermis has a form called a ‘brick and mortar structure’. Skin tissue goes through a continuous self-recovery process, and scales that have completed the differentiation process constantly repeat the process of being shed from the skin tissue. It has been revealed that microorganisms influence these changes in the skin.
일반적으로 노화된 피부에서는 진피에 존재하는 기질 단백질의 변화로 인해 주름살과 피부의 탄력 감소, 피부 처짐 및 건조 현상 등이 나타난다. 진피는 피부 내에서 피부의 강도와 형태를 지지하는 역할을 하고 있기 때문에, 노화가 진행될 때 이 영역에서의 형태적인 변화가 일어나게 되면, 주름 생성 및 피부 처짐에 결정적인 역할을 하게 된다. 이러한 기질 단백질을 분해하는 효소로 Matrix metalloproteinases(MMPs)가 대표적이며, 한 번의 자외선 조사에도 피부 내의 MMPs 활성이 증가되고, 피부 내의 콜라겐 및 기타 기질 단백질을 분해하여 피부 노화를 촉진하는데 주요한 요인으로 작용한다.In general, in aging skin, wrinkles, decreased skin elasticity, sagging skin, and dryness appear due to changes in matrix proteins present in the dermis. Because the dermis plays a role in supporting the strength and shape of the skin, when morphological changes occur in this area as aging progresses, it plays a critical role in wrinkle formation and skin sagging. Matrix metalloproteinases (MMPs) are representative enzymes that decompose these matrix proteins. Even a single UV irradiation increases the activity of MMPs in the skin, and acts as a major factor in promoting skin aging by decomposing collagen and other matrix proteins in the skin. .
피부 노화 중 광노화는 피부의 가장 큰 노화 인자로 고려되고 있으며, 이에 따라 광노화를 예방하기 위한 제품이 많이 출시되고 있으나, 천연 소재를 이용한 광노화 방지 기술은 사용이 제한적이고 효능 검증시 여러 가지 문제가 발생하는 경우가 많다는 한계가 있다.Among skin aging, photoaging is considered the biggest aging factor of the skin, and accordingly, many products to prevent photoaging are being released. However, photoaging prevention technology using natural materials is limited in use and various problems arise when verifying efficacy. There are limitations in many cases.
따라서, 상기와 같은 문제점을 개선하기 위하여 미생물 발효 혼합물과 기능성 물질을 포함함으로써 피부 상태 개선의 시너지 효과를 발휘할 수 있는 기능성 화장품을 개발할 필요가 있다.Therefore, in order to improve the above problems, there is a need to develop functional cosmetics that can exert a synergistic effect in improving skin condition by including a microbial fermentation mixture and functional substances.
일 양상은 스타필로코커스 속(Staphylococcus sp.) 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; 스트렙토코커스 속(Streptococcus sp.) 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; 쿠티박테리움 속(Cutibacterium sp.) 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; 인하이드로박터 속(Enhydrobacter sp.) 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; 및 DNA 단편 혼합물을 유효성분으로 포함하는 피부 상태 개선용 조성물을 제공하는 것이다.One aspect is a Staphylococcus sp. strain, its lysate, culture, extract of the culture, or a mixture thereof; Streptococcus sp. strain, its lysate, culture, extract of the culture, or mixtures thereof; Cutibacterium sp. strain, its lysate, culture, extract of the culture, or mixtures thereof; Enhydrobacter sp. strain, its lysate, culture medium, extract of the culture medium, or mixtures thereof; and a composition for improving skin condition comprising a DNA fragment mixture as an active ingredient.
다른 양상은 유효량의 상기한 조성물을 그를 필요로 하는 개체에 처리 또는 투여하는 단계를 포함하는 개체의 상태를 예방, 개선, 또는 치료하는 방법을 제공한다.Another aspect provides a method of preventing, ameliorating, or treating a condition in a subject comprising treating or administering an effective amount of the composition described above to the subject in need thereof.
다른 양상은 피부 상태 개선용 조성물을 제조하는 데 사용하기 위한, 상기 4종의 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; 및 DNA 단편 혼합물의 용도를 제공하는 것이다.Another aspect includes the above-mentioned four strains, their lysate, culture medium, extract of the culture medium, or mixtures thereof for use in preparing a composition for improving skin condition; and the use of DNA fragment mixtures.
일 양상은 스타필로코커스 속(Staphylococcus sp.) 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; 스트렙토코커스 속(Streptococcus sp.) 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; 쿠티박테리움 속(Cutibacterium sp.) 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; 인하이드로박터 속(Enhydrobacter sp.) 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; 및 DNA 단편 혼합물을 유효성분으로 포함하는 조성물을 제공한다. One aspect is a Staphylococcus sp. strain, its lysate, culture, extract of the culture, or a mixture thereof; Streptococcus sp. strain, its lysate, culture, extract of the culture, or mixtures thereof; Cutibacterium sp. strain, its lysate, culture, extract of the culture, or mixtures thereof; Enhydrobacter sp. strain, its lysate, culture medium, extract of the culture medium, or mixtures thereof; and a DNA fragment mixture as an active ingredient.
본 명세서에서 용어 "파쇄액"은 "용해물"과 상호교환적으로 사용될 수 있으며, 화학적 또는 물리적 힘에 의하여 균주의 세포벽을 파쇄하여 얻은 산물을 의미할 수 있다. 상기 파쇄액은 파쇄액 자체, 그의 농축물 또는 동결건조물을 포함할 수 있다.As used herein, the term “lysate” may be used interchangeably with “lysate” and may refer to a product obtained by breaking the cell wall of a strain by chemical or physical force. The lysate may include the lysate itself, its concentrate, or its freeze-dried product.
본 명세서에서 용어 "배양액"은 "배양 상층액", "조건 배양액" 또는 "조정 배지"와 호환적으로 사용될 수 있고, 스타필로코커스 속, 스트렙토코커스 속, 쿠티박테리움 속, 및/또는 인하이드로박터 속 균주가 시험관 내에서 성장 및 생존할 수 있도록 영양분을 공급할 수 있는 배지에 상기 균주를 일정기간 배양하여 얻는 상기 균주, 이의 대사물, 여분의 영양분 등을 포함하는 전체 배지를 의미할 수 있다. 또한, 상기 배양액은 균주를 배양하여 얻은 균체 배양액에서 균체를 제거한 배양액을 의미할 수 있다. 한편, 상기 배양액 중 균체를 제거한 액체를 "상층액"이라고도 하며, 상기 상층액은 배양액을 일정시간 가만히 두어 하층에 가라앉은 부분을 제외한 상층의 액체만을 취하거나, 여과를 통해 균체를 제거하거나, 배양액을 원심분리하여 하부의 침전을 제거하고 상부의 액체만을 취하여 획득할 수 있다. 상기 "균체"는 본 발명의 균주 자체를 의미하는 것으로 샘플 등으로부터 분리하여 선별한 균주 자체 또는 상기 균주를 배양하여 배양액으로부터 분리한 균주를 포함한다. 상기 균체는 배양액을 원심분리하여 하층에 가라앉은 부분을 취하여 획득할 수 있고, 또는 중력에 의해 배양액의 하층으로 가라앉으므로 일정 시간동안 가만히 두었다가 상부의 액체를 제거함으로써 획득할 수 있다.As used herein, the term “culture” may be used interchangeably with “culture supernatant,” “conditioned culture,” or “conditioned medium,” and may be used interchangeably with the genus Staphylococcus, Streptococcus, Cutibacterium, and/or Inhydro. It may refer to the entire medium containing the strain, its metabolites, extra nutrients, etc. obtained by culturing the strain for a certain period of time in a medium that can supply nutrients so that the Bacter strain can grow and survive in vitro. Additionally, the culture medium may refer to a culture medium obtained by removing the bacterial cells from the bacterial culture medium obtained by culturing the strain. On the other hand, the liquid from which the bacteria have been removed from the culture medium is also called "supernatant", and the supernatant is obtained by leaving the culture solution still for a certain period of time and taking only the upper liquid excluding the part that has settled in the lower layer, or by removing the bacteria through filtration, or by removing the culture liquid. It can be obtained by centrifuging to remove the sediment at the bottom and taking only the liquid at the top. The "bacteria" refers to the strain itself of the present invention, and includes the strain itself separated and selected from a sample, etc., or a strain isolated from the culture medium by culturing the strain. The bacterial cells can be obtained by centrifuging the culture medium and taking the part that has sunk to the lower layer. Alternatively, since they sink to the lower layer of the culture medium by gravity, they can be obtained by leaving them still for a certain period of time and then removing the upper liquid.
상기 균주를 배양하기 위한 배양용 배지 및 배양 조건은 통상의 지식을 가진 자가 적절하게 선택하거나 변형하여 이용할 수 있다. 예를 들어, 상기 배양액은 스타필로코커스 속, 스트렙토코커스 속, 쿠티박테리움 속, 및/또는 인하이드로박터 속 균주를 배지(예: R2A, TSB, TSA, BHI 또는 RCM 배지)에서 적절한 온도(예: 10℃ 초과 또는 40℃ 미만 중 어느 온도)에서 일정 시간(예: 4 내지 120시간) 동안 배양하여 수득된 것일 수 있다. Culture media and culture conditions for cultivating the above strain can be appropriately selected or modified by those skilled in the art. For example, the culture medium includes strains of the genus Staphylococcus, Streptococcus, Cutibacterium, and/or Inhydrobacter in a medium (e.g., R2A, TSB, TSA, BHI or RCM medium) at an appropriate temperature (e.g. : It may be obtained by culturing for a certain period of time (e.g., 4 to 120 hours) at any temperature above 10°C or below 40°C.
상기 배양액은 균주를 배양하여 수득된 배양액 자체, 그의 농축물, 또는 동결건조물 또는 배양액로부터 균주를 제거하여 수득된 배양 상층액, 그의 농축물 또는 동결건조물을 포함할 수 있다. The culture medium may include the culture medium itself, its concentrate, or freeze-dried product obtained by cultivating the strain, or the culture supernatant obtained by removing the strain from the culture medium, its concentrate, or freeze-dried product.
일 구체예에서, 균주의 배양 상층액은 균주 배양액을 원심분리 또는 여과시켜 균주를 제거하는 단계에 의해 수득될 수 있다.In one embodiment, the culture supernatant of the strain may be obtained by removing the strain by centrifuging or filtering the strain culture fluid.
다른 구체예에서, 농축물은 상기 균주 배양액 자체, 또는 상기 배양액을 원심분리 또는 여과한 후 수득된 상층액을 농축하는 단계에 의해 수득될 수 있다. In another embodiment, the concentrate may be obtained by concentrating the strain culture itself or the supernatant obtained after centrifuging or filtering the culture.
본 명세서에서 용어 "배양액 추출물"은 상기 배양액 또는 그의 농축액로부터 추출한 것을 의미하며, 추출액, 추출액의 희석액 또는 농축액, 추출액을 건조하여 얻어지는 건조물, 또는 이들 조정제물 또는 정제물, 이를 분획한 분획물을 포함할 수 있다. As used herein, the term "culture extract" refers to an extract from the culture medium or its concentrate, and may include extracts, diluted or concentrated extracts, dried products obtained by drying the extracts, crude or purified products thereof, and fractions thereof. You can.
상기 균주, 그의 파쇄액, 배양액, 또는 배양액의 추출물은 생물학적으로 순수한 것일 수 있다. 상기 균주는 순수배양(pure culture)에 의해 얻은 것일 수 있다.The strain, its lysate, culture medium, or extract of the culture medium may be biologically pure. The strain may be obtained by pure culture.
일 실시예에서는 스타필로코커스 속, 스트렙토코커스 속, 쿠티박테리움 속, 인하이드로박터 속 균주 및 DNA 단편 혼합물이 자외선에 의해 감소된 유전자 마커 COL1A1 및 엘라스틴(ELN)의 발현을 증가시키고, 피부 보습 관련 인자(예: HAS3) 및 피부 장벽 관련 인자(예: ABCA12)의 발현을 증가시키는 것을 확인하였다. 따라서, 상기 조성물은 피부 상태 개선, 피부 미용 개선, 피부 질환의 예방, 개선 또는 치료 등에 사용될 수 있다. In one embodiment, a mixture of strains and DNA fragments of the genus Staphylococcus, Streptococcus, Cutibacterium, and Inhydrobacter increase the expression of genetic markers COL1A1 and elastin (ELN), which are reduced by ultraviolet rays, and increase the expression of genes related to skin moisturization. It was confirmed that the expression of factors (eg, HAS3) and skin barrier-related factors (eg, ABCA12) was increased. Therefore, the composition can be used to improve skin condition, improve skin beauty, prevent, improve or treat skin diseases, etc.
상기 피부 상태 개선 또는 피부 미용 개선은 피부 노화 방지(항노화), 피부 주름 개선(항주름), 피부 탄력 증진, 피부 보습, 또는 피부 장벽 강화일 수 있다. The improvement of skin condition or skin beauty may be preventing skin aging (anti-aging), improving skin wrinkles (anti-wrinkle), improving skin elasticity, moisturizing skin, or strengthening the skin barrier.
본 명세서에서 용어 "피부 노화"란 나이가 들어가면서 피부에 나타나게 되는 유형과 무형상의 변화를 통틀어 말한다. 피부 노화는 예컨대 표피 두께가 얇아지는 현상, 진피의 세포 수나 혈관 수의 감소, DNA 손상 복구 능력의 감소, 세포교체주기의 증가, 상처 회복 능력 감소, 피부 장벽기능 약화, 표피의 수분 유지 능력 감소, 땀분비 감소, 피지분비 감소, 비타민D 생산 감소, 물리적 손상 방어 능력 감소, 화학물질 제거능력 감소, 면역반응 감소, 감각 기능 약화, 체온조절의 감소 등을 포함한다. As used herein, the term “skin aging” refers to both tangible and intangible changes that occur in the skin as one ages. Skin aging includes, for example, a thinning of the epidermis, a decrease in the number of cells or blood vessels in the dermis, a decrease in the ability to repair DNA damage, an increase in the cell turnover cycle, a decrease in the ability to heal wounds, a weakening of the skin barrier function, a decrease in the moisture retention ability of the epidermis, These include reduced sweat secretion, reduced sebum secretion, reduced vitamin D production, reduced ability to defend against physical damage, reduced ability to eliminate chemicals, reduced immune response, weakened sensory function, and reduced body temperature regulation.
상기 피부 노화 방지는 외인성 요인 또는 내인성 요인에 의해 유발되는 피부 노화를 개선하는 것일 수 있다. 상기 외인성 요인은 여러 가지 외부 요인, 예컨대 자외선(광)을 말한다. 상기 내인성 요인은 연대기적 요인이라고도 지칭되며 주로 시간의 흐름에 의해 발생하는 요인을 말한다. 즉, 상기 피부 노화는 구체적으로는 자외선, 공해, 담배연기, 화학물질 등에 의한 외부 자극에 의해 유도되는 조기 노화 증상뿐만 아니라, 나이가 들어감에 의해 피부세포의 증식이 감소함에 따라 발생하는 자연노화 현상을 포함하며, 주름 및 탄력 감소, 피부 처짐 및 건조 현상 등을 모두 포함하는 개념이다. 또한 주름은 내ㆍ외부 요인의 변화에 의한 자극이 피부조직을 구성하고 있는 성분을 변화시켜 주름을 유발하는 것을 포함한다. The prevention of skin aging may mean improving skin aging caused by extrinsic or endogenous factors. The exogenous factors refer to various external factors, such as ultraviolet rays (light). The endogenous factors are also referred to as chronological factors and mainly refer to factors that occur due to the passage of time. In other words, the skin aging is specifically not only a symptom of premature aging induced by external stimuli such as ultraviolet rays, pollution, cigarette smoke, chemicals, etc., but also a natural aging phenomenon that occurs as the proliferation of skin cells decreases with age. It is a concept that includes wrinkles, loss of elasticity, skin sagging and dryness, etc. In addition, wrinkles include stimulation caused by changes in internal and external factors that change the components that make up skin tissue, causing wrinkles.
상기 노화는 광노화일 수 있다. 용어 "광노화(Photoaging)"는 외부 환경적인 요인에 의해 유발되는 현상으로, 가장 대표적인 인자로는 자외선이 있다. 자외선은 단백질 분해효소의 활성화와 기질단백질의 사슬절단 및 비정상적인 교차결합 등의 생체 구성 성분들의 손상을 가져오고, 이러한 메커니즘의 반복은 외관상으로도 확연한 피부노화를 초래하게 된다. The aging may be photoaging. The term “photoaging” is a phenomenon caused by external environmental factors, the most representative factor being ultraviolet rays. Ultraviolet rays cause damage to biological components such as activation of proteolytic enzymes, chain cutting of matrix proteins, and abnormal cross-linking, and repetition of this mechanism causes skin aging that is evident in appearance.
용어 "주름"은 피부의 탄력성이 상실되어 느슨해진 상태를 의미하며, 예를 들면 피부가 접히는 것일 수 있다. 상기 "피부 주름 예방 또는 개선"이란 주름과 관련된 인자의 발현을 억제하여 주름을 방지 또는 개선하거나, 콜라겐 총량을 증가시키는 모든 작용을 의미할 수 있다.The term “wrinkle” refers to a state in which the skin loses its elasticity and becomes loose, for example, the skin may be folded. The term “prevention or improvement of skin wrinkles” may refer to any action that prevents or improves wrinkles by suppressing the expression of factors related to wrinkles, or increases the total amount of collagen.
상기 "피부 보습"은 피부 수분을 유지하거나 수분 손실을 방지하는 모든 작용을 의미할 수 있다.The term “skin moisturizing” may refer to any action that maintains skin moisture or prevents moisture loss.
상기 "피부 장벽 강화"는 피부 가장 바깥쪽에 위치하여 수분과 영양 손실을 막아주는 피부 장벽의 기능이 증진되는 모든 작용을 의미할 수 있다.The “skin barrier strengthening” may refer to any action that improves the function of the skin barrier, which is located on the outermost layer of the skin and prevents moisture and nutrition loss.
상기 "피부 질환"은 피부 장벽 기능 손상에 의한 질환, 피부 노화, 피부 상처, 피부 흉터, 또는 피부 염증일 수 있다. The “skin disease” may be a disease caused by damage to the skin barrier function, skin aging, skin wound, skin scar, or skin inflammation.
용어, "예방"은 질병의 발생을 억제하는 것을 포함한다. 용어, "치료"는 질병의 발전의 억제, 경감, 또는 제거를 포함한다. 용어 "개선"은 상태의 완화 또는 치료와 관련된 파라미터, 예를 들면 증상의 정도를 적어도 감소시키는 모든 행위를 의미할 수 있다.The term “prevention” includes suppressing the occurrence of a disease. The term “treatment” includes inhibiting, alleviating, or eliminating the development of a disease. The term “improvement” may refer to any action that results in at least reducing the severity of a parameter associated with the alleviation or treatment of a condition, such as symptoms.
상기 피부 장벽 기능 손상은 피부 장벽의 기능이 저하되거나 손상되어 피부에 나타나는 모든 변화를 의미할 수 있다. 예를 들어, 피부 주름 증가, 건조, 피부염, 아토피 피부염, 알레르기성 피부염, 여드름 등을 포함할 수 있다.The damage to the skin barrier function may mean any change that appears in the skin due to decreased or damaged skin barrier function. For example, it may include increased skin wrinkles, dryness, dermatitis, atopic dermatitis, allergic dermatitis, acne, etc.
상기 스타필로코커스 속(Staphylococcus sp.) 균주는 예를 들어, 스타필로코커스 에피데르미디스(Staphylococcus epidermidis), 스타필로코커스 호미니스(Staphylococcus hominis), 스타필로코커스 와르네리(Staphylococcus warneri), 스타필로코커스 카프라에(Staphylococcus caprae), 스타필로코커스 캐피티스(Staphylococcus capitis) 등인 것일 수 있다. The Staphylococcus sp. strains include, for example, Staphylococcus epidermidis , Staphylococcus hominis , Staphylococcus warneri , Staphylococcus caprae , It may be Staphylococcus capitis , etc.
일 구체예에 있어서, 상기 스타필로코커스 속 균주는 스타필로코커스 에피데르미디스(Staphylococcus epidermidis)(수탁번호: KCCM12559P)인 것일 수 있다. In one embodiment, the Staphylococcus genus strain may be Staphylococcus epidermidis (Accession Number: KCCM12559P).
다른 구체예에 있어서, 상기 스타필로코커스 속 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물은 조성물 총 중량에 대하여 5 내지 20 중량%로 포함되는 것일 수 있다. 상기 스타필로코커스 속 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물은 조성물 총 중량에 대하여 예를 들어, 5 내지 20 중량%, 5 내지 18 중량%, 5 내지 16 중량%, 7 내지 20 중량%, 7 내지 17 중량%, 8 내지 15 중량% 또는 10 내지 13 중량%로 포함될 수 있다. 이때, 상기 스타필로코커스 속 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물의 함량이 상기 범위 미만이거나 또는 상기 범위를 초과하는 경우, 피부 상태 개선 효과를 충분히 발휘할 수 없다는 문제점이 있다. In another embodiment, the Staphylococcus genus strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof may be included in an amount of 5 to 20% by weight based on the total weight of the composition. The Staphylococcus genus strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof is, for example, 5 to 20% by weight, 5 to 18% by weight, 5 to 16% by weight, 7 to 7% by weight, based on the total weight of the composition. It may be included at 20% by weight, 7 to 17% by weight, 8 to 15% by weight, or 10 to 13% by weight. At this time, if the content of the Staphylococcus genus strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof is less than or exceeds the above range, there is a problem that the effect of improving skin condition cannot be sufficiently exerted.
상기 스트렙토코커스 속(Streptococcus sp.) 균주는 예를 들어, 스트렙토코커스 써모필러스(Streptococcus thermophiles), 스트렙토코커스 미티스(Streptococcus mitis), 스트렙토코커스 인판티스(Streptococcus infantis), 스트렙토코커스 뉴모니에(streptococcus pneumonia) 등인 것일 수 있다. The Streptococcus genus ( Streptococcus sp.) strains are, for example, Streptococcus thermophiles, Streptococcus mitis , Streptococcus infantis , It may be Streptococcus pneumoniae , etc.
일 구체예에 있어서, 상기 스트렙토코커스 속 균주는 스트렙토코커스 써모필러스(Streptococcus thermophiles)(수탁번호: KCCM12004P)인 것일 수 있다. In one embodiment, the Streptococcus genus strain may be Streptococcus thermophiles (Accession number: KCCM12004P).
다른 구체예에 있어서, 상기 스트렙토코커스 속 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물은 조성물 총 중량에 대하여 5 내지 30 중량%로 포함되는 것일 수 있다. 상기 스트렙토코커스 속 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물은 조성물 총 중량에 대하여 5 내지 30 중량%, 5 내지 28 중량%, 5 내지 25 중량%, 5 내지 20 중량%, 8 내지 30 중량%, 8 내지 24 중량%, 8 내지 18 중량%, 10 내지 27 중량%, 10 내지 20 중량% 또는 10 내지 15 중량%로 포함될 수 있다. 이때, 상기 스트렙토코커스 속 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물의 함량이 상기 범위 미만이거나 또는 상기 범위를 초과하는 경우, 피부 상태 개선 효과를 충분히 발휘할 수 없다는 문제점이 있다. In another embodiment, the Streptococcus genus strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof may be included in an amount of 5 to 30% by weight based on the total weight of the composition. The Streptococcus genus strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof is contained in an amount of 5 to 30% by weight, 5 to 28% by weight, 5 to 25% by weight, 5 to 20% by weight, 8%, based on the total weight of the composition. It may be included in an amount of from 30% by weight, 8 to 24% by weight, 8 to 18% by weight, 10 to 27% by weight, 10 to 20% by weight, or 10 to 15% by weight. At this time, if the content of the Streptococcus genus strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof is less than or exceeds the above range, there is a problem that the effect of improving skin condition cannot be sufficiently exerted.
상기 쿠티박테리움 속(Cutibacterium sp.) 균주는 예를 들어, 큐티박테리움 아크네스(Cutibacterium acnes), 큐티박테리움 그래뉼러섬(cutibacterium granulosum) 등인 것일 수 있다. The Cutibacterium sp. strain may be, for example, Cutibacterium acnes , Cutibacterium granulosum , etc.
일 구체예에 있어서, 상기 쿠티박테리움 속 균주는 큐티박테리움 아크네스(Cutibacterium acnes)(수탁번호: KCCM12680P)인 것일 수 있다. In one embodiment, the strain of the Cutibacterium genus may be Cutibacterium acnes (Accession Number: KCCM12680P).
다른 구체예에 있어서, 상기 쿠티박테리움 속 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물은 조성물 총 중량에 대하여 50 내지 90 중량%로 포함되는 것일 수 있다. 상기 쿠티박테리움 속 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물은 조성물 종 중량에 대하여 예를 들어, 50 내지 90 중량%, 50 내지 80 중량%, 50 내지 70 중량%, 55 내지 90 중량%, 55 내지 85 중량%, 55 내지 75 중량%, 60 내지 90 중량%, 60 내지 80 중량% 또는 70 내지 75 중량%로 포함될 수 있다. 이때, 상기 쿠티박테리움 속 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물의 함량이 상기 범위 미만이거나 또는 상기 범위를 초과하는 경우, 피부 상태 개선 효과를 충분히 발휘할 수 없다는 문제점이 있다. In another embodiment, the Cutibacterium genus strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof may be included in an amount of 50 to 90% by weight based on the total weight of the composition. The Cutibacterium genus strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof is, for example, 50 to 90% by weight, 50 to 80% by weight, 50 to 70% by weight, 55 to 55% by weight, based on the weight of the species of the composition. It may be included at 90% by weight, 55 to 85% by weight, 55 to 75% by weight, 60 to 90% by weight, 60 to 80% by weight, or 70 to 75% by weight. At this time, if the content of the Cutibacterium genus strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof is less than or exceeds the above range, there is a problem that the skin condition improvement effect cannot be sufficiently exerted.
상기 인하이드로박터 속(Enhydrobacter sp.) 균주는 예를 들어, 인하이드로박터 에어로사커스(Enhydrobacter aerosaccus)(수탁번호: KCCM13073P)인 것일 수 있다. The Enhydrobacter sp. strain may be, for example, Enhydrobacter aerosaccus (Accession number: KCCM13073P).
일 구체예에 있어서, 상기 인하이드로박터 속 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물은 조성물 총 중량에 대하여 0.5 내지 10 중량%로 포함되는 것일 수 있다. 상기 인하이드로박터 속 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물은 조성물 총 중량에 대하여 예를 들어, 0.5 내지 10 중량%, 0.5 내지 8 중량%, 0.5 내지 5 중량%, 1 내지 7 중량%, 1 내지 6 중량%, 2 내지 9 중량%, 또는 2 내지 5 중량%로 포함될 수 있다. 이때, 상기 인하이드로박터 속 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물의 함량이 상기 범위 미만이거나 또는 상기 범위를 초과하는 경우, 피부 상태 개선 효과를 충분히 발휘할 수 없다는 문제점이 있다. In one embodiment, the Inhydrobacter genus strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof may be included in an amount of 0.5 to 10% by weight based on the total weight of the composition. The Inhydrobacter genus strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof is, for example, 0.5 to 10% by weight, 0.5 to 8% by weight, 0.5 to 5% by weight, 1 to 1% by weight, based on the total weight of the composition. It may be included at 7% by weight, 1 to 6% by weight, 2 to 9% by weight, or 2 to 5% by weight. At this time, if the content of the Inhydrobacter genus strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof is less than or exceeds the above range, there is a problem that the effect of improving skin condition cannot be sufficiently exerted.
본 명세서에서 용어, "DNA 단편 혼합물"은 인산, 4종류의 염기 및 데옥시리보오스(deoxyribose)로 이루어진 생체 고분자에 해당하는 DNA가 추출된 형태로서 다양한 분자량을 갖는 DNA 단편 형태로 혼합되어 존재한다. As used herein, the term "DNA fragment mixture" is a form in which DNA corresponding to a biopolymer composed of phosphoric acid, four types of bases, and deoxyribose is extracted and exists in a mixture of DNA fragments having various molecular weights.
일 구체예에 있어서, 상기 DNA 단편 혼합물은 가수분해(hydrolyzed)된 것일 수 있다. In one embodiment, the DNA fragment mixture may be hydrolyzed.
상기 DNA 단편 혼합물은 예를 들어, 폴리데옥시리보뉴클레오티드(polydeoxyribonucleotide; PDRN), 폴리뉴클레오티드(polynucleotide) 등인 것일 수 있다. 상기 폴리데옥시리보뉴클레오티드(polydeoxyribonucleotide; PDRN)는 짧은 데옥시리보뉴클레오타이드(short deoxyribonucleotide)의 혼합물(mixture)로서, DNA사슬을 일정 크기로 분획화하여 만든 저분자량 DNA 복합체(low molecular weight DNA complex)의 일종이다. 또한, 상기 폴리뉴클레오티드(polynucleotide)는 뉴클레오티드 단위체(monomer)가 공유결합에 의해 사슬모양으로 이어진 뉴클레오티드의 중합체(polymer)로 일정한 길이 이상의 DNA 또는 RNA 가닥을 의미한다. 상기 폴리뉴클레오티드는 예를 들어, 폴리데옥시리보뉴클레오티드에 비해 상대적으로 핵산의 길이가 길거나 분자량이 큰 것일 수 있으나, 이에 제한되지 않는다. The DNA fragment mixture may be, for example, polydeoxyribonucleotide (PDRN), polynucleotide, etc. The polydeoxyribonucleotide (PDRN) is a mixture of short deoxyribonucleotides, a low molecular weight DNA complex made by fractionating DNA chains to a certain size. It's kind of like that. In addition, the polynucleotide refers to a DNA or RNA strand of a certain length or more, which is a polymer of nucleotides in which nucleotide monomers are connected in a chain shape by covalent bonds. For example, the polynucleotide may have a relatively longer nucleic acid length or a higher molecular weight than a polydeoxyribonucleotide, but is not limited thereto.
다른 구체예에 있어서, 상기 DNA 단편 혼합물의 분자량은 50 내지 10,000 kDa인 것일 수 있다. 상기 DNA 단편 혼합물의 분자량은 예를 들어, 50 내지 10,000 kDa, 50 내지 5,000 kDa, 50 내지 3,000 kDa, 50 내지 1,500 kDa, 1,000 내지 10,000 kDa, 1,000 내지 5,000 kDa 또는 5,000 내지 10,000 kDa인 것일 수 있다.In another embodiment, the molecular weight of the DNA fragment mixture may be 50 to 10,000 kDa. The molecular weight of the DNA fragment mixture may be, for example, 50 to 10,000 kDa, 50 to 5,000 kDa, 50 to 3,000 kDa, 50 to 1,500 kDa, 1,000 to 10,000 kDa, 1,000 to 5,000 kDa, or 5,000 to 10,000 kDa.
다른 구체예에 있어서, 상기 DNA 단편 혼합물은 어류의 정소 또는 정액에서 추출하여 수득한 DNA 단편 혼합물인 것일 수 있으며, 상기 어류는 연어과, 구체적으로 연어 또는 송어인 것일 수 있다. In another embodiment, the DNA fragment mixture may be a mixture of DNA fragments obtained by extraction from testes or semen of a fish, and the fish may be a salmonid, specifically salmon or trout.
다른 구체예에 있어서, 상기 DNA 단편 혼합물은 조성물 총 중량에 대하여 0.01 내지 1 중량%로 포함되는 것일 수 있다. 상기 DNA 단편 혼합물은 조성물 총 중량에 대하여 예를 들어, 0.01 내지 1 중량%, 0.01 내지 0.7 중량%, 0.03 내지 0.7 중량%, 0.1 내지 0.8 중량% 또는 0.3 내지 0.6 중량%로 포함될 수 있다. 이때, 상기 DNA 단편 혼합물의 함량이 상기 범위 미만이거나 또는 상기 범위를 초과하는 경우, 피부 상태 개선 효과를 충분히 발휘할 수 없다는 문제점이 있다. In another embodiment, the DNA fragment mixture may be included in an amount of 0.01 to 1% by weight based on the total weight of the composition. The DNA fragment mixture may be included, for example, at 0.01 to 1% by weight, 0.01 to 0.7% by weight, 0.03 to 0.7% by weight, 0.1 to 0.8% by weight, or 0.3 to 0.6% by weight, based on the total weight of the composition. At this time, if the content of the DNA fragment mixture is less than or exceeds the above range, there is a problem that the skin condition improvement effect cannot be sufficiently exhibited.
상기 조성물은 스타필로코커스 속, 스트렙토코커스 속, 쿠티박테리움 속, 인하이드로박터 속 균주 및 DNA 단편 혼합물을 특정 중량비로 포함함으로써 피부 상태 개선의 시너지 활성을 갖는 것일 수 있다. The composition may have synergistic activity in improving skin condition by containing strains of the genus Staphylococcus, Streptococcus, Cutibacterium, and Inhydrobacter and a mixture of DNA fragments in a specific weight ratio.
일 구체예에 있어서, 상기 스타필로코커스 속 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; 스트렙토코커스 속 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; 쿠티박테리움 속 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; 인하이드로박터 속 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; 및 DNA 단편 혼합물은 1:1 내지 2:5 내지 7:0.1 내지 0.5:0.01 내지 0.06의 중량비로 혼합된 것일 수 있다. 상기 스타필로코커스 속, 스트렙토코커스 속, 쿠티박테리움 속, 인하이드로박터 속 균주 및 DNA 단편 혼합물은 예를 들어, 1:1 내지 2:5 내지 7:0.1 내지 0.5:0.01 내지 0.06, 1:1 내지 1.5:5 내지 6.5:0.1 내지 0.3:0.01 내지 0.05, 또는 1:1 내지 1.3:5.5 내지 7:0.2 내지 0.5:0.03 내지 0.05의 중량비로 혼합된 것일 수 있다. 이때, 상기 스타필로코커스 속, 스트렙토코커스 속, 쿠티박테리움 속, 인하이드로박터 속 균주 및 DNA 단편 혼합물의 혼합 중량비가 상기 범위 미만이거나 또는 상기 범위를 초과하는 경우, 피부 상태 개선 효과를 충분히 발휘할 수 없다는 문제점이 있다. In one embodiment, the Staphylococcus genus strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof; Streptococcus strains, their lysate, culture medium, extract of the culture medium, or mixtures thereof; Cutibacterium genus strains, their lysate, culture medium, extract of the culture medium, or mixtures thereof; Inhydrobacter genus strains, their lysate, culture medium, extract of the culture medium, or mixtures thereof; And the DNA fragment mixture may be mixed at a weight ratio of 1:1 to 2:5 to 7:0.1 to 0.5:0.01 to 0.06. The mixture of strains and DNA fragments of the Staphylococcus genus, Streptococcus genus, Cutibacterium genus, and Inhydrobacter genus is, for example, 1:1 to 2:5 to 7:0.1 to 0.5:0.01 to 0.06, 1:1 It may be mixed at a weight ratio of 1.5:5 to 6.5:0.1 to 0.3:0.01 to 0.05, or 1:1 to 1.3:5.5 to 7:0.2 to 0.5:0.03 to 0.05. At this time, when the mixing weight ratio of the Staphylococcus genus, Streptococcus genus, Cutibacterium genus, Inhydrobacter genus strain and DNA fragment mixture is less than or exceeds the above range, the skin condition improvement effect can be sufficiently exhibited. There is a problem that there is no.
따라서, 일 양상에 따른 조성물은 스타필로코커스 속(Staphylococcus sp.) 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; 스트렙토코커스 속(Streptococcus sp.) 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; 쿠티박테리움 속(Cutibacterium sp.) 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; 인하이드로박터 속(Enhydrobacter sp.) 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; 및 DNA 단편 혼합물을 특정 함량 및 중량비로 포함함으로써 피부 상태 개선의 시너지 효과를 발휘할 수 있다. Accordingly, the composition according to one aspect includes a Staphylococcus sp. strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof; Streptococcus sp. strain, its lysate, culture, extract of the culture, or mixtures thereof; Cutibacterium sp. strain, its lysate, culture, extract of the culture, or mixtures thereof; Enhydrobacter sp. strain, its lysate, culture medium, extract of the culture medium, or mixtures thereof; and a DNA fragment mixture in a specific content and weight ratio can exert a synergistic effect in improving skin condition.
본 명세서에서 용어, "유효성분으로 포함"은 상기에서 언급한 효과를 나타낼 수 있는 정도로 본 명세서의 균주, 이의 파쇄액, 배양액, 또는 배양액의 추출물; 및/또는 DNA 단편 혼합물이 첨가되는 것을 의미하고, 약물전달 및 안정화 등을 위하여 다양한 성분을 부성분으로 첨가하여 다양한 형태로 포뮬레이션 (formulation)되는 것을 포함하는 의미이다.As used herein, the term "included as an active ingredient" refers to the strain of the present specification, its lysate, culture medium, or extract of the culture medium to the extent that it can exhibit the above-mentioned effects; and/or DNA fragment mixture is added, and includes formulation in various forms by adding various ingredients as sub-ingredients for drug delivery and stabilization.
일 구체예에 있어서, 상기 조성물은 화장료 조성물일 수 있다. In one embodiment, the composition may be a cosmetic composition.
상기 화장료 조성물은 본 명세서에 개시된 유효성분 이외에 화장료 조성물에 통상적으로 이용되는 성분들, 기능성 첨가물 등을 추가로 포함할 수 있으며, 예컨대 항산화제, 안정화제, 용해화제, 계면활성제, 분산제, 유화제, 방부제, 비타민, 안료, 향료 등과 같은 통상적인 보조제, 그리고 담체를 포함할 수 있다. In addition to the active ingredients disclosed in this specification, the cosmetic composition may further include ingredients commonly used in cosmetic compositions, functional additives, etc., such as antioxidants, stabilizers, solubilizers, surfactants, dispersants, emulsifiers, and preservatives. , conventional auxiliaries such as vitamins, pigments, fragrances, etc., and carriers.
상기 화장료 조성물은 특정 제형에 특별히 한정되지 않으며, 목적하는 바에 따라 제형을 적절히 선택할 수 있다. 상기 화장료 조성물은, 예를 들어, 가용화 제형, 유화 제형, 또는 분산 제형을 갖는 것일 수 있다. 상기 화장료 조성물은 예를 들면, 화장수, 크림, 에센스, 클렌징 폼, 클렌징 워터, 팩, 앰플, 바디 로션, 바디 오일, 바디 젤, 샴푸, 린스, 헤어 컨디셔너, 헤어 젤, 파운데이션, 립스틱, 마스카라, 메이크업 베이스, 또는 피부 점착 타입의 화장료 제형을 갖는 것일 수 있다. 상기 피부 점착 타입의 화장료 제형은 예를 들어, 마스크팩일 수 있으나, 이에 제한되지 않는다.The cosmetic composition is not particularly limited to a specific formulation, and the formulation may be appropriately selected depending on the purpose. The cosmetic composition may have, for example, a solubilized formulation, an emulsified formulation, or a dispersed formulation. The cosmetic composition includes, for example, lotion, cream, essence, cleansing foam, cleansing water, pack, ampoule, body lotion, body oil, body gel, shampoo, rinse, hair conditioner, hair gel, foundation, lipstick, mascara, and makeup. It may have a base or skin-adhesive cosmetic formulation. The skin-adhesive cosmetic formulation may be, for example, a mask pack, but is not limited thereto.
다른 구체예에 있어서, 상기 조성물은 피부외용제용 조성물일 수 있다. In another embodiment, the composition may be a composition for external application to the skin.
상기 피부외용제는 크림, 겔, 연고, 피부 유화제, 피부 현탁액, 경피전달성 패치, 약물 함유 붕대, 로션, 또는 그 조합일 수 있다. 상기 피부외용제는 통상 화장품이나 의약품 등의 피부외용제에 사용되는 성분, 예를 들면 수성성분, 유성성분, 분말성분, 알코올류, 보습제, 증점제, 자외선흡수제, 미백제, 방부제, 산화방지제, 계면활성제, 향료, 색제, 각종 피부 영양제, 금속이온봉쇄제, 당류, 또는 이들의 조합과 필요에 따라서 적절하게 배합될 수 있다. The external skin preparation may be a cream, gel, ointment, skin emulsifier, skin suspension, transdermal delivery patch, drug-containing bandage, lotion, or a combination thereof. The skin external preparations include ingredients commonly used in external skin preparations such as cosmetics and medicines, such as aqueous ingredients, oil-based ingredients, powder ingredients, alcohols, moisturizers, thickeners, ultraviolet absorbers, whitening agents, preservatives, antioxidants, surfactants, and fragrances. , colorants, various skin nutrients, metal ion sequestrants, sugars, or combinations thereof may be appropriately mixed as needed.
다른 구체예에 있어서, 상기 조성물은 건강기능식품 조성물일 수 있다. In another embodiment, the composition may be a health functional food composition.
상기 건강기능식품 조성물은 상기 유효성분 단독을 사용하거나, 또는 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 혼합 양은 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조시에 본 명세서의 조성물은 원료에 대하여 15 중량부 이하의 양으로 첨가될 수 있다. 상기 건강기능식품의 종류에는 특별한 제한은 없다. 건강기능식품의 종류 중 음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드; 말토스, 슈크로스와 같은 디사카라이드; 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드; 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 건강식품 조성물은 또한 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제, 또는 그 조합을 함유할 수 있다. 상기 건강기능식품 조성물은 또한, 천연 과일쥬스, 과일쥬스 음료, 야채 음료의 제조를 위한 과육, 또는 그 조합을 함유할 수 있다.The health functional food composition may be used alone or in combination with other foods or food ingredients, and may be used appropriately according to conventional methods. The mixing amount of the active ingredient can be appropriately determined depending on the purpose of use (prevention, health, or therapeutic treatment). In general, when manufacturing food or beverages, the composition of the present specification may be added in an amount of 15 parts by weight or less based on the raw materials. There are no particular restrictions on the types of health functional foods. Among the types of health functional foods, beverage compositions may contain various flavoring agents or natural carbohydrates as additional ingredients like ordinary beverages. The natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; and polysaccharides such as dextrins and cyclodextrins; Sugar alcohols such as xylitol, sorbitol, and erythritol. As a sweetener, natural sweeteners such as thaumatin and stevia extract or synthetic sweeteners such as saccharin and aspartame can be used. The health food composition also contains nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, and carbonated beverages. It may contain the carbonating agent used, or a combination thereof. The health functional food composition may also contain pulp for the production of natural fruit juice, fruit juice beverage, vegetable beverage, or a combination thereof.
다른 양상은 유효량의 상기한 조성물을 그를 필요로 하는 개체에 처리 또는 투여하는 단계를 포함하는 개체의 상태를 예방, 개선, 또는 치료하는 방법을 제공한다. Another aspect provides a method of preventing, ameliorating, or treating a condition in a subject comprising treating or administering an effective amount of the composition described above to the subject in need thereof.
상기 개체의 상태는 피부와 관련된 상태와 관련된 상태일 수 있고, 구체적으로, 피부 장벽 기능 손상에 의한 질환, 피부 노화일 수 있다. The condition of the subject may be a condition related to skin-related conditions, and specifically, may be a disease caused by damage to the skin barrier function or skin aging.
용어 "유효량"이란 상기에서 언급한 효과를 나타낼 수 있을 정도로 유효한 양을 의미한다.The term “effective amount” refers to an amount effective enough to produce the above-mentioned effects.
본 명세서에서 용어, "투여하는", "도입하는", 및 "이식하는"은 상호교환적으로 사용되고, 일 구체예에 따른 조성물의 원하는 부위로의 적어도 부분적 국소화를 초래하는 방법 또는 경로에 의한 개체 내로의 일 구체예에 따른 조성물의 배치를 의미할 수 있다. As used herein, the terms “administering,” “introducing,” and “implanting” are used interchangeably and refer to an individual by a method or route that results in at least partial localization of the composition according to one embodiment to the desired site. It may refer to the arrangement of the composition according to one embodiment into the inner space.
투여는 당업계에 알려진 방법에 의한 것일 수 있다. 투여 경로, 투여 횟수 등의 투여 방법은 통상의 기술자가 적절히 선택할 수 있다. 투여는 예를 들면, 정맥내, 근육내, 경구, 경피(transdermal), 점막, 코안(intranasal), 기관내(intratracheal) 또는 피하 투여와 같은 경로로, 임의의 수단에 의하여 개체로 직접적으로 투여될 수 있다. 상기 투여는 전신적으로 또는 국부적으로 투여될 수 있다. 상기 투여는 피부에의 도포를 포함할 수 있다.Administration may be by methods known in the art. The administration method, such as administration route and administration frequency, can be appropriately selected by a person skilled in the art. Administration may be administered directly to the subject by any means, such as, for example, intravenous, intramuscular, oral, transdermal, mucosal, intranasal, intratracheal or subcutaneous administration. You can. The administration may be administered systemically or locally. The administration may include application to the skin.
상기 개체는 포유동물, 예를 들면, 사람, 소, 말, 돼지, 개, 양, 염소, 또는 고양이일 수 있다. 상기 개체는 피부 상태 개선을 필요로 하는 개체, 예를 들어 피부 노화 방지, 피부 주름 개선, 피부 탄력 증진, 피부 보습, 피부 장벽 강화, 피부 염증 억제 효과를 필요로 하는 개체일 수 있다.The subject may be a mammal, such as a human, cow, horse, pig, dog, sheep, goat, or cat. The subject may be an entity that requires improvement of skin condition, for example, an entity that requires anti-aging skin, improvement of skin wrinkles, enhancement of skin elasticity, skin moisturization, strengthening of skin barrier, and inhibition of skin inflammation.
상기 투여는 일 구체예에 따른 조성물을 개체당 일당 0.1 ㎎ 내지 1,000 ㎎, 예를 들면, 0.1 ㎎ 내지 500 ㎎, 0.1 ㎎ 내지 100 ㎎, 0.1 ㎎ 내지 50 ㎎, 0.1 ㎎ 내지 25 ㎎, 1 ㎎ 내지 1,000 ㎎, 1 ㎎ 내지 500 ㎎, 1 ㎎ 내지 100 ㎎, 1 ㎎ 내지 50 ㎎, 1 ㎎ 내지 25 ㎎, 5 ㎎ 내지 1,000 ㎎, 5 ㎎ 내지 500 ㎎, 5 ㎎ 내지 100 ㎎, 5 ㎎ 내지 50 ㎎, 5 ㎎ 내지 25 ㎎, 10 ㎎ 내지 1,000 ㎎, 10 ㎎ 내지 500 ㎎, 10 ㎎ 내지 100 ㎎, 10 ㎎ 내지 50 ㎎, 또는 10 ㎎ 내지 25 ㎎을 투여하는 것일 수 있다. 다만, 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성별, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하게 처방될 수 있고, 당업자라면 이러한 요인들을 고려하여 투여량을 적절히 조절할 수 있다. 투여 횟수는 1일 1회 또는 임상적으로 용인가능한 부작용의 범위 내에서 2회 이상이 가능하다. 투여 부위에 대해서도 1개소 또는 2개소 이상에 투여할 수 있으며, 매일 또는 2 내지 5일 간격으로 총 투여 일수는 한번 치료 시 1일에서 30일까지 투여될 수 있다. 필요한 경우, 적정 시기 이후에 동일한 치료를 반복할 수 있다. 인간 이외의 동물에 대해서도, kg당 인간과 동일한 투여량으로 하거나, 또는 예를 들면 목적의 동물과 인간과의 기관(심장 등)의 용적비(예를 들면, 평균값) 등으로 상기의 투여량을 환산한 양을 투여할 수 있다.The administration of the composition according to one embodiment is 0.1 mg to 1,000 mg, for example, 0.1 mg to 500 mg, 0.1 mg to 100 mg, 0.1 mg to 50 mg, 0.1 mg to 25 mg, 1 mg to 1 mg per day. 1,000 mg, 1 mg to 500 mg, 1 mg to 100 mg, 1 mg to 50 mg, 1 mg to 25 mg, 5 mg to 1,000 mg, 5 mg to 500 mg, 5 mg to 100 mg, 5 mg to 50 mg , 5 mg to 25 mg, 10 mg to 1,000 mg, 10 mg to 500 mg, 10 mg to 100 mg, 10 mg to 50 mg, or 10 mg to 25 mg. However, the dosage may be prescribed in various ways depending on factors such as formulation method, administration method, patient's age, weight, gender, pathological condition, food, administration time, administration route, excretion rate, and reaction sensitivity, and those skilled in the art will Taking these factors into consideration, the dosage can be adjusted appropriately. The frequency of administration can be once a day or two or more times within the range of clinically acceptable side effects. Regarding the administration site, it can be administered at one or two or more locations, and the total number of administration days can be from 1 to 30 days for one treatment, either daily or at intervals of 2 to 5 days. If necessary, the same treatment can be repeated after an appropriate period. For animals other than humans, the dosage per kg is the same as for humans, or the above dosage is converted into, for example, the volume ratio (e.g., average value) of the organs (heart, etc.) between the target animal and human. One dose can be administered.
다른 양상은 피부 상태 개선용 조성물을 제조하는 데 사용하기 위한, 상기 4종의 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; 및 DNA 단편 혼합물의 용도를 제공한다.Another aspect includes the above-mentioned four strains, their lysate, culture medium, extract of the culture medium, or mixtures thereof for use in preparing a composition for improving skin condition; and uses of DNA fragment mixtures.
중복되는 내용은 본 명세서의 복잡성을 고려하여 생락하며, 본 명세서에서 달리 정의되지 않은 용어들은 본 발명이 속하는 기술분야에서 통상적으로 사용되는 의미를 갖는 것이다.Redundant content is omitted in consideration of the complexity of the present specification, and terms not otherwise defined in the present specification have meanings commonly used in the technical field to which the present invention pertains.
일 양상에 따른 조성물은 콜라겐, 엘라스틴, HAS3 및 ABCA12의 발현을 증가시키는 바, 피부 노화, 피부 보습, 피부 장벽 강화, 피부 주름, 또는 피부 탄력과 같은 피부 상태 개선에 유용하게 사용될 수 있다.The composition according to one aspect increases the expression of collagen, elastin, HAS3, and ABCA12, and can be usefully used to improve skin conditions such as skin aging, skin moisturizing, skin barrier strengthening, skin wrinkles, or skin elasticity.
도 1은 일 양상에 따른 조성물이 COL1A1 발현에 미치는 영향을 나타낸 결과이다. Figure 1 is a result showing the effect of a composition according to one aspect on COL1A1 expression.
도 2는 일 양상에 따른 조성물이 ELN 발현에 미치는 영향을 나타낸 결과이다.Figure 2 is a result showing the effect of a composition according to one aspect on ELN expression.
도 3은 일 양상에 따른 조성물이 HAS3 발현에 미치는 영향을 나타낸 결과이다.Figure 3 is a result showing the effect of a composition according to one aspect on HAS3 expression.
도 4는 일 양상에 따른 조성물이 ABCA12 발현에 미치는 영향을 나타낸 결과이다.Figure 4 is a result showing the effect of a composition according to one aspect on ABCA12 expression.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시한다. 그러나 하기의 실시예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 하기 실시예에 의해 본 발명의 내용이 한정되는 것은 아니다.Below, preferred embodiments are presented to aid understanding of the present invention. However, the following examples are provided only to make the present invention easier to understand, and the content of the present invention is not limited by the following examples.
[제조예][Manufacturing example]
제조예 1. 스타필로코커스 에피데르미디스 균주 배양액의 제조Preparation Example 1. Preparation of Staphylococcus epidermidis strain culture medium
스타필로코커스 에피데르미디스 균주 배양액을 제조하였다. 구체적으로, 한국미생물보존센터(Korean Culture Center of Microorganisms, KCCM)로부터 스타필로코커스 에피데르미디스(Staphylococcus epidermidis) 균주(수탁번호: KCCM12559P)를 분양 받아 R2A(Reasoner's 2A) 배지에서 150 rpm/min으로 현탁하여 증균 배양하였다. 배양 기간 동안 온도를 약 30℃로 유지하여 주고, 72시간 동안 배양한 후, 0.45 ㎛ 필터를 사용하여 배양액을 여과하였다. Staphylococcus epidermidis strain culture medium was prepared. Specifically, Staphylococcus epidermidis strain (Accession number: KCCM12559P) was received from the Korean Culture Center of Microorganisms (KCCM) and grown at 150 rpm/min in R2A (Reasoner's 2A) medium. It was suspended and cultured for enrichment. The temperature was maintained at about 30°C during the culturing period, and after culturing for 72 hours, the culture medium was filtered using a 0.45 ㎛ filter.
제조예 2. 스트렙토코커스 썰모필러스 균주 배양액의 제조Preparation Example 2. Preparation of Streptococcus thermophilus strain culture medium
스트렙토코커스 썰모필러스(Streptococcus thermophiles) 균주(수탁번호: KCCM12004P) 및 TSB(Tryptic Soy Broth) 배지를 사용하였다는 점을 제외하고는 상기 제조예 1과 동일한 방법으로 스트렙토코커스 썰모필러스 균주 배양액을 제조하였다. Streptococcus thermophiles strain (Accession number: KCCM12004P) and TSB (Tryptic Soy Broth) medium were used, except that Streptococcus thermophiles strain culture medium was prepared in the same manner as in Preparation Example 1 . did.
제조예 3. 쿠티박테리움 아크네스 균주 배양액의 제조Preparation Example 3. Preparation of Coutibacterium acnes strain culture medium
쿠티박테리움 아크네스(Cutibacterium acnes) 균주(수탁번호: KCCM12680P) 및 RCM(Reinforced Clostridial Medium) 배지를 사용하여 정치 배양하였다는 점을 제외하고는 상기 제조예 1과 동일한 방법으로 쿠티박테리움 아크네스 균주 배양액을 제조하였다. Cutibacterium acnes strain (Accession number: KCCM12680P) was prepared in the same manner as in Preparation Example 1 except that it was stationary cultured using RCM (Reinforced Clostridial Medium) medium. Culture medium was prepared.
제조예 4. 인하이드로박터 에어로사커스 균주 배양액의 제조Preparation Example 4. Preparation of Inhydrobacter Aerosarcus strain culture medium
인하이드로박터 에어로사커스(Enhydrobacter aerosaccus) 균주(수탁번호: KCCM13073P)를 사용하였다는 점을 제외하고는 상기 제조예 3과 동일한 방법으로 인하이드로박터 에어로사커스 균주 배양액을 제조하였다. An Enhydrobacter aerosaccus strain culture medium was prepared in the same manner as in Preparation Example 3, except that the Enhydrobacter aerosaccus strain (accession number: KCCM13073P) was used.
[실시예][Example]
실시예 1. 균주 배양액 및 DNA 단편 혼합물을 포함하는 조성물의 제조Example 1. Preparation of a composition comprising strain culture medium and DNA fragment mixture
하기 표 1의 성분 및 함량을 포함하는 조성물을 제조하였다. 구체적으로, 제조예 1~4의 배양액과 분자량 50~1,500 kDa의 hydrolyzed DNA(㈜파마리서치 제조)을 혼합하여 조성물을 제조하였다. 상기 hydrolyzed DNA는 흰색 또는 미백색 분말의 DNA 단편 혼합물이다. 본 명세서에서 다른 언급이 없는 한 함량은 중량%이다. A composition containing the ingredients and contents shown in Table 1 below was prepared. Specifically, a composition was prepared by mixing the culture media of Preparation Examples 1 to 4 with hydrolyzed DNA (manufactured by Pharma Research Co., Ltd.) with a molecular weight of 50 to 1,500 kDa. The hydrolyzed DNA is a mixture of DNA fragments in a white or off-white powder. Unless otherwise stated herein, content is in weight percent.
성분ingredient 함량content
제조예 1Manufacturing Example 1 1111
제조예 2Production example 2 1414
제조예 3Production example 3 71.571.5
제조예 4Production example 4 33
hydrolyzed DNAhydrolyzed DNA 0.50.5
[비교예][Comparative example]
비교예 1. 균주 배양액을 포함하는 조성물의 제조Comparative Example 1. Preparation of a composition containing strain culture medium
하기 표 2의 성분 및 함량을 포함하였다는 점을 제외하고는 상기 실시예 1과 동일한 방법으로 조성물을 제조하였다.The composition was prepared in the same manner as Example 1, except that it included the ingredients and contents shown in Table 2 below.
비교예 1은 실시예 1과 균주 배양액의 혼합 비율이 동일하나, hydrolyzed DNA 대신 멸균 증류수를 포함하는 점에서 차이가 있다.Comparative Example 1 has the same mixing ratio of the strain culture medium as Example 1, but differs in that it contains sterilized distilled water instead of hydrolyzed DNA.
성분ingredient 비교예 1Comparative Example 1
제조예 1Manufacturing Example 1 1111
제조예 2Production example 2 1414
제조예 3Production example 3 71.571.5
제조예 4Production example 4 33
멸균 증류수sterile distilled water 0.50.5
비교예 2. 균주 배양액 및 DNA 단편 혼합물을 포함하는 조성물의 제조Comparative Example 2. Preparation of a composition containing strain culture medium and DNA fragment mixture
하기 표 3의 성분 및 함량을 포함하였다는 점을 제외하고는 상기 실시예 1과 동일한 방법으로 조성물을 제조하였다.The composition was prepared in the same manner as Example 1, except that it included the ingredients and contents shown in Table 3 below.
비교예 2는 실시예 1과 균주 배양액의 혼합 비율에 차이가 있다.Comparative Example 2 differs from Example 1 in the mixing ratio of the strain culture medium.
성분ingredient 비교예 2Comparative Example 2
제조예 1Manufacturing example 1 24.87524.875
제조예 2Production example 2 24.87524.875
제조예 3Production example 3 24.87524.875
제조예 4Production example 4 24.87524.875
hydrolyzed DNAhydrolyzed DNA 0.50.5
[실험예][Experimental example]
실험예 1. 항노화, 항주름, 피부 탄력 증진 활성 확인Experimental Example 1. Confirmation of anti-aging, anti-wrinkle, and skin elasticity promotion activities
일 양상에 따른 조성물의 피부 노화, 주름 개선, 피부 탄력 증진 활성을 확인하였다. The skin aging, wrinkle improvement, and skin elasticity enhancing activities of the composition according to one aspect were confirmed.
1-1. 세포 배양 및 시료 처리1-1. Cell culture and sample processing
인간 섬유아세포 세포주(Human dermal fibroblast, Hs68)를 6 웰 플레이트에 3.5x105로 분주한 후, 37℃, 5% CO2 조건의 배양기에서 24 시간 동안 배양하였다. 이후 배지를 제거하고 DPBS(Dulbecco's phosphate-buffered saline)를 넣은 후 20 mJ/cm2의 UVB를 조사하거나 조사하지 않았다. UVB 조사 직후 DPBS를 제거하고 FBS fetal bovin serum)가 없는 배지로 교체한 후, 상기 실시예 및 비교예에서 제조한 조성물을 처리하고 24시간 동안 추가 배양하였다. 음성 대조군으로 자외선 처리 및 균주 배양액 비처리군을 사용하였다. Human dermal fibroblast (Hs68) cell line was distributed at 3.5x10 5 in a 6-well plate and cultured in an incubator at 37°C and 5% CO 2 for 24 hours. Afterwards, the medium was removed, DPBS (Dulbecco's phosphate-buffered saline) was added, and 20 mJ/cm 2 UVB was irradiated or not. Immediately after UVB irradiation, DPBS was removed and replaced with medium without FBS fetal bovin serum, and then treated with the composition prepared in the above Examples and Comparative Examples and further cultured for 24 hours. As a negative control group, a group untreated with ultraviolet rays and strain culture was used.
1-2. 유전자 발현 수준 분석1-2. Gene expression level analysis
그 후 각 시료의 세포에서 트리졸(RNA iso, DAKARA, 일본)을 이용하여 RNA를 분리한 뒤 나노드롭(nanodrop)으로 260 ㎚에서 RNA를 정량한 후, 각각 2㎍의 RNA를 사용하여 증폭기에서 cDNA를 합성하였다(C1000 Thermal Cycler, Bio-Rad, 미국). 합성된 cDNA를 주형으로 사이버그린 (SYBR Green supermix, Applied Biosystems, USA) 및 프라이머(COL1A1용 프라이머, 또는 ELN용 프라이머)를 첨가하여 실시간(real-time) PCR 기계(Step One Plus, AppliedBiosystems, 미국)에서 실시간 중합효소 연쇄반응을 수행하였다. 유전자의 발현량은 β-actin 유전자에 대한 보정을 통해 최종적으로 분석하였다. Afterwards, RNA was isolated from the cells of each sample using Trizol (RNA iso, DAKARA, Japan), RNA was quantified at 260 nm using a nanodrop, and 2 μg of RNA was used in an amplifier. cDNA was synthesized (C1000 Thermal Cycler, Bio-Rad, USA). Using the synthesized cDNA as a template, Cybergreen (SYBR Green supermix, Applied Biosystems, USA) and primers (primers for COL1A1 or primers for ELN) were added to a real-time PCR machine (Step One Plus, AppliedBiosystems, USA). Real-time polymerase chain reaction was performed. The expression level of the gene was finally analyzed through correction for the β-actin gene.
1-3. 결과1-3. result
도 1은 일 양상에 따른 조성물이 COL1A1 발현에 미치는 영향을 나타낸 결과이다. Figure 1 is a result showing the effect of a composition according to one aspect on COL1A1 expression.
도 2는 일 양상에 따른 조성물이 ELN 발현에 미치는 영향을 나타낸 결과이다. Figure 2 is a result showing the effect of a composition according to one aspect on ELN expression.
그 결과, 도 1 및 도 2에 나타낸 바와 같이, 자외선 조사에 의하여 섬유아세포주에서 COL1A1 및 엘라스틴의 발현이 감소하였고, 실시예 1 및 비교예 1~2의 처리에 의하여 COL1A1 및 엘라스틴의 발현이 증가하는 것을 확인할 수 있었다. 구체적으로, 실시예 1은 비교예 1 및 비교예 2와 비교하여 COL1A1 및 엘라스틴의 발현이 유의하게 증가하는 것을 확인할 수 있었다. As a result, as shown in Figures 1 and 2, the expression of COL1A1 and elastin in the fibroblast cell line was decreased by ultraviolet irradiation, and the expression of COL1A1 and elastin was increased by the treatment of Example 1 and Comparative Examples 1 and 2. I was able to confirm that Specifically, in Example 1, it was confirmed that the expression of COL1A1 and elastin was significantly increased compared to Comparative Examples 1 and 2.
즉, 일 양상에 따른 조성물은 4가지 종류의 균주 배양액 및 DNA 단편 혼합물을 유효성분으로 포함함으로써 자외선에 의해 감소된 COL1A1 및 엘라스틴의 발현을 증가시키는 바, 피부 노화(예: 광노화) 방지(항노화), 주름 개선(항주름), 피부 탄력 증진에 효과가 있다. That is, the composition according to one aspect increases the expression of COL1A1 and elastin, which are reduced by ultraviolet rays, by including four types of strain cultures and a mixture of DNA fragments as active ingredients, thereby preventing skin aging (e.g. photoaging) (anti-aging) ), is effective in improving wrinkles (anti-wrinkle) and improving skin elasticity.
실험예 2. 피부 보습 활성 확인Experimental Example 2. Confirmation of skin moisturizing activity
일 양상에 따른 조성물의 피부 보습 활성을 확인하였다. The skin moisturizing activity of the composition according to one aspect was confirmed.
2-1. 세포 배양 및 시료 처리2-1. Cell culture and sample processing
인간 각질형성 세포주(human keratinocyte)인 HaCaT 세포를 10% 우혈청 (fetal bovine serum)을 포함한 DMEM 배지(Dulbecco's modified Eagle's Medium, Gibco 1210-0038)에서 배양하였고, 배양은 모두 37℃, 5% CO2 배양기에서 수행하였다. 상기 배양된 세포주에 상기 실시예 및 비교예에서 제조한 조성물을 처리하여 24시간 동안 추가 배양하였다. HaCaT cells, a human keratinocyte cell line, were cultured in DMEM medium (Dulbecco's modified Eagle's Medium, Gibco 1210-0038) containing 10% fetal bovine serum, and all cultures were performed at 37°C and 5% CO 2 It was performed in an incubator. The cultured cell lines were treated with the compositions prepared in the Examples and Comparative Examples and further cultured for 24 hours.
2-2. 유전자 발현 수준 분석2-2. Gene expression level analysis
HAS3(히알루론산 합성 효소)용 프라이머를 사용한 것을 제외하고는 실험예 1-2와 동일한 방법을 사용하여 HAS3 유전자 발현 수준을 분석하였다.The HAS3 gene expression level was analyzed using the same method as Experimental Example 1-2, except that primers for HAS3 (hyaluronic acid synthase) were used.
2-3. 결과2-3. result
도 3은 일 양상에 따른 조성물이 HAS3 발현에 미치는 영향을 나타낸 결과이다. Figure 3 is a result showing the effect of a composition according to one aspect on HAS3 expression.
그 결과, 도 3에 나타낸 바와 같이, 실시예 1은 비교예 1~2와 비교하여 HAS3 발현이 유의하게 증가한 것을 확인할 수 있었다. As a result, as shown in Figure 3, it was confirmed that HAS3 expression in Example 1 was significantly increased compared to Comparative Examples 1 and 2.
즉, 일 양상에 따른 조성물은 4가지 종류의 균주 배양액 및 DNA 단편 혼합물을 유효성분으로 포함함으로써 HAS3의 발현을 유의하게 증가시키는 바, 피부 보습 개선에 유용하게 사용될 수 있다. That is, the composition according to one aspect significantly increases the expression of HAS3 by including four types of strain cultures and a mixture of DNA fragments as active ingredients, and can be usefully used to improve skin moisturization.
실험예 3. 피부 장벽 기능 개선 활성 확인Experimental Example 3. Confirmation of skin barrier function improvement activity
일 양상에 따른 조성물의 피부 장벽 기능 개선 활성을 확인하였다. The skin barrier function improvement activity of the composition according to one aspect was confirmed.
3-1. 세포 배양 및 시료 처리3-1. Cell culture and sample processing
인간 각질형성세포주(human keratinocyte)인 HaCaT 세포에 인터페론 생산을 촉진하는 합성 리보핵산인 폴리 IC(polyinosinic:polycytidylic acid; Poly I:C)를 처리한 후, 24시간 동안 배양하여 HaCaT 세포주를 자극하였다. 이후, 자극에 의해 노화된 세포에 상기 실시예 및 비교예에서 제조한 조성물 1%(w/w)을 처리하고 24시간 동안 추가 배양하였다.HaCaT cells, a human keratinocyte cell line, were treated with polyIC (polyinosinic:polycytidylic acid; Poly I:C), a synthetic ribonucleic acid that promotes interferon production, and then cultured for 24 hours to stimulate the HaCaT cell line. Thereafter, cells aged by stimulation were treated with 1% (w/w) of the composition prepared in the above Examples and Comparative Examples and further cultured for 24 hours.
3-2. 유전자 발현 수준 분석 3-2. Gene expression level analysis
이후, RNA를 추출하고, 나노드롭(nanodrop)을 사용하여 RNA를 정량하였다. RNA 16 ㎕를 정량하여 70℃에서 5분 동안 처리한 후, PCR 프리믹스(premix)에 넣고 약하게 볼택싱(vertexing)하였다. 이후 42℃에서 55분 처리하고, 70℃에서 15분 처리하고, 4℃에 보관하여 cDNA를 합성하였다. 합성한 cDNA를 PCR를 이용하여 증폭하였다. cDNA 2 ㎕, ABCA12(ATP-binding cassette sub-family A member 12) 유전자를 타겟으로 하는 정방향 프라이머 1 ㎕와 역방향 프라이머 1 ㎕, 증류수 6 ㎕, 프리믹스(premix) 시료 10 ㎕를 혼합한 후, 95℃ 3분, {95℃ 30초, 49 내지 53℃ 30초, 72℃ 1분} 40 사이클을 처리하여 증폭하였다.Afterwards, RNA was extracted and quantified using nanodrop. 16 ㎕ of RNA was quantified and treated at 70°C for 5 minutes, then added to PCR premix and gently vortexed. Afterwards, cDNA was synthesized by treating at 42°C for 55 minutes, at 70°C for 15 minutes, and storing at 4°C. The synthesized cDNA was amplified using PCR. After mixing 2 ㎕ of cDNA, 1 ㎕ of forward primer targeting the ABCA12 (ATP-binding cassette sub-family A member 12) gene, 1 ㎕ of reverse primer, 6 ㎕ of distilled water, and 10 ㎕ of premix sample, the mixture was stored at 95°C. Amplification was performed through 40 cycles of 3 minutes, {95°C 30 seconds, 49 to 53°C 30 seconds, 72°C 1 minute}.
3-3. 결과3-3. result
도 4는 일 양상에 따른 조성물이 ABCA12 발현에 미치는 영향을 나타낸 결과이다. Figure 4 is a result showing the effect of a composition according to one aspect on ABCA12 expression.
그 결과, 도 4에 나타낸 바와 같이, 실시예 1은 비교예 1~2와 비교하여 ABCA12 발현이 유의하게 증가한 것을 확인할 수 있었다. As a result, as shown in Figure 4, it was confirmed that ABCA12 expression in Example 1 was significantly increased compared to Comparative Examples 1 and 2.
즉, 일 양상에 따른 조성물은 4가지 종류의 균주 배양액 및 DNA 단편 혼합물을 유효성분으로 포함함으로써, ABCA12의 발현을 유의하게 증가시키는 바, 피부 장벽 개선에 유용하게 사용될 수 있다. That is, the composition according to one aspect significantly increases the expression of ABCA12 by including four types of strain cultures and a mixture of DNA fragments as active ingredients, and can be usefully used to improve the skin barrier.
종합하면, 일 양상에 따른 조성물은 4가지 종류의 균주 배양액 및 DNA 단편 혼합물을 포함함으로써, (i) 자외선에 의해 감소된 COL1A1 및 ELN의 발현을 증가시키는 효과, (ii) HAS3의 발현을 증가시키는 효과, (iii) ABCA12의 발현을 증가시키는 효과를 갖는다. 또한, 상기 (i) 내지 (iii)의 효과는 DNA 단편 혼합물을 포함하지 않는 비교예 1 또는 균주 배양액의 혼합 비율이 다른 비교예 2에 비해 유의적으로 우수함을 확인하였다.In summary, the composition according to one aspect includes a mixture of four types of strain cultures and DNA fragments, thereby (i) increasing the expression of COL1A1 and ELN reduced by ultraviolet rays, (ii) increasing the expression of HAS3 effect, (iii) has the effect of increasing the expression of ABCA12. In addition, it was confirmed that the effects of (i) to (iii) were significantly better than those of Comparative Example 1, which did not contain a mixture of DNA fragments, or Comparative Example 2, which had a different mixing ratio of the strain culture medium.
전술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야의 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다.The description of the present invention described above is for illustrative purposes, and those skilled in the art will understand that the present invention can be easily modified into other specific forms without changing the technical idea or essential features of the present invention. will be. Therefore, the embodiments described above should be understood in all respects as illustrative and not restrictive.

Claims (11)

  1. 스타필로코커스 속(Staphylococcus sp.) 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; Staphylococcus sp. strain, its lysate, culture, extract of the culture, or mixtures thereof;
    스트렙토코커스 속(Streptococcus sp.) 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; Streptococcus sp. strain, its lysate, culture, extract of the culture, or mixtures thereof;
    쿠티박테리움 속(Cutibacterium sp.) 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; Cutibacterium sp. strain, its lysate, culture, extract of the culture, or mixtures thereof;
    인하이드로박터 속(Enhydrobacter sp.) 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; 및 Enhydrobacter sp. strain, its lysate, culture medium, extract of the culture medium, or mixtures thereof; and
    DNA 단편 혼합물을 유효성분으로 포함하는 피부 상태 개선용 화장료 조성물.A cosmetic composition for improving skin condition comprising a mixture of DNA fragments as an active ingredient.
  2. 청구항 1에 있어서, 상기 피부 상태 개선은 피부 노화 방지, 피부 주름 개선, 피부 탄력 증진, 피부 보습, 또는 피부 장벽 강화인 것인 화장료 조성물.The cosmetic composition according to claim 1, wherein the improving skin condition includes preventing skin aging, improving skin wrinkles, improving skin elasticity, moisturizing skin, or strengthening the skin barrier.
  3. 청구항 1에 있어서, 상기 스타필로코커스 속 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물은 조성물 총 중량에 대하여 5 내지 25 중량%로 포함되는 것인 화장료 조성물. The cosmetic composition according to claim 1, wherein the Staphylococcus genus strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof is contained in an amount of 5 to 25% by weight based on the total weight of the composition.
  4. 청구항 1에 있어서, 상기 스트렙토코커스 속 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물은 조성물 총 중량에 대하여 5 내지 30 중량%로 포함되는 것인 화장료 조성물. The cosmetic composition according to claim 1, wherein the Streptococcus genus strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof is contained in an amount of 5 to 30% by weight based on the total weight of the composition.
  5. 청구항 1에 있어서, 상기 쿠티박테리움 속 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물은 조성물 총 중량에 대하여 50 내지 90 중량%로 포함되는 것인 화장료 조성물. The cosmetic composition according to claim 1, wherein the Cutibacterium genus strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof is contained in an amount of 50 to 90% by weight based on the total weight of the composition.
  6. 청구항 1에 있어서, 상기, 인하이드로박터 속 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물은 조성물 총 중량에 대하여 0.5 내지 10 중량%로 포함되는 것인 화장료 조성물. The cosmetic composition according to claim 1, wherein the Inhydrobacter genus strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof is contained in an amount of 0.5 to 10% by weight based on the total weight of the composition.
  7. 청구항 1에 있어서, 상기 DNA 단편 혼합물은 조성물 총 중량에 대하여 0.01 내지 1 중량%로 포함되는 것인 화장료 조성물. The cosmetic composition according to claim 1, wherein the DNA fragment mixture is contained in an amount of 0.01 to 1% by weight based on the total weight of the composition.
  8. 청구항 1에 있어서, 상기 DNA 단편 혼합물은 폴리데옥시리보뉴클레오티드(polydeoxyribonucleotide), 폴리뉴클레오티드(polynucleotide) 또는 이들의 혼합물인 것인 화장료 조성물. The cosmetic composition according to claim 1, wherein the DNA fragment mixture is polydeoxyribonucleotide, polynucleotide, or a mixture thereof.
  9. 청구항 1에 있어서, 상기 DNA 단편 혼합물의 분자량은 50 내지 10,000 kDa인 것인 화장료 조성물. The cosmetic composition according to claim 1, wherein the molecular weight of the DNA fragment mixture is 50 to 10,000 kDa.
  10. 청구항 1에 있어서, In claim 1,
    상기 스타필로코커스 속 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; The Staphylococcus genus strain, its lysate, culture medium, extract of the culture medium, or mixtures thereof;
    스트렙토코커스 속 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물;Streptococcus strains, their lysate, culture medium, extract of the culture medium, or mixtures thereof;
    쿠티박테리움 속 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물;Cutibacterium genus strains, their lysate, culture medium, extract of the culture medium, or mixtures thereof;
    인하이드로박터 속 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; 및 Inhydrobacter genus strains, their lysate, culture medium, extract of the culture medium, or mixtures thereof; and
    DNA 단편 혼합물은 1:1 내지 2:5 내지 7:0.1 내지 0.5:0.01 내지 0.06의 중량비로 혼합된 것인 화장료 조성물. A cosmetic composition in which the DNA fragment mixture is mixed at a weight ratio of 1:1 to 2:5 to 7:0.1 to 0.5:0.01 to 0.06.
  11. 스타필로코커스 속(Staphylococcus sp.) 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; Staphylococcus sp. strain, its lysate, culture, extract of the culture, or mixtures thereof;
    스트렙토코커스 속(Streptococcus sp.) 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; Streptococcus sp. strain, its lysate, culture, extract of the culture, or mixtures thereof;
    쿠티박테리움 속(Cutibacterium sp.) 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; Cutibacterium sp. strain, its lysate, culture, extract of the culture, or mixtures thereof;
    인하이드로박터 속(Enhydrobacter sp.) 균주, 그의 파쇄액, 배양액, 배양액의 추출물 또는 이들의 혼합물; 및 Enhydrobacter sp. strain, its lysate, culture medium, extract of the culture medium, or mixtures thereof; and
    DNA 단편 혼합물을 유효성분으로 포함하는 피부 상태 개선용 피부외용제 조성물.An external skin composition for improving skin condition comprising a DNA fragment mixture as an active ingredient.
PCT/KR2023/009049 2022-07-27 2023-06-28 Cosmetic composition comprising staphylococcus sp. strain, streptococcus sp. strain, cutibacterium sp. strain, enhydrobacter sp. strain, and dna fragment mixture WO2024025173A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2022-0093390 2022-07-27
KR1020220093390A KR102569532B1 (en) 2022-07-27 2022-07-27 Cosmetic composition comprising strains of Staphylococcus genus, Streptococcus genus, Cutibacterium genus, Enhydrobacter and fragmented DNA mixture

Publications (1)

Publication Number Publication Date
WO2024025173A1 true WO2024025173A1 (en) 2024-02-01

Family

ID=87841333

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/009049 WO2024025173A1 (en) 2022-07-27 2023-06-28 Cosmetic composition comprising staphylococcus sp. strain, streptococcus sp. strain, cutibacterium sp. strain, enhydrobacter sp. strain, and dna fragment mixture

Country Status (2)

Country Link
KR (1) KR102569532B1 (en)
WO (1) WO2024025173A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180121268A (en) * 2017-04-28 2018-11-07 코스맥스 주식회사 Composition comprising Streptococcus thermophilus strain and culture medium thereof
KR20210037294A (en) * 2019-09-27 2021-04-06 코스맥스 주식회사 Staphylococcus epidermidis ST-6 strain and skin condition improving uses of thereof
KR102273950B1 (en) * 2020-05-08 2021-07-08 코스맥스 주식회사 Cutibacterium acnes subsp. acnes strain and skin condition improving uses of thereof
KR102415344B1 (en) * 2021-05-04 2022-06-30 주식회사 파마리서치 Skin wrinkle improvement composition comprising fragmented DNA mixtures with increased skin permeability

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180121268A (en) * 2017-04-28 2018-11-07 코스맥스 주식회사 Composition comprising Streptococcus thermophilus strain and culture medium thereof
KR20210037294A (en) * 2019-09-27 2021-04-06 코스맥스 주식회사 Staphylococcus epidermidis ST-6 strain and skin condition improving uses of thereof
KR102273950B1 (en) * 2020-05-08 2021-07-08 코스맥스 주식회사 Cutibacterium acnes subsp. acnes strain and skin condition improving uses of thereof
KR102415344B1 (en) * 2021-05-04 2022-06-30 주식회사 파마리서치 Skin wrinkle improvement composition comprising fragmented DNA mixtures with increased skin permeability

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Information on the Results of the 20th Ingredient Name Standardization Committee in 2021", KCA, 1 November 2021 (2021-11-01), XP093132549, Retrieved from the Internet <URL:https://kcia.or.kr/cid/cs/notice.php?type=view&no=14180&ss=page%3D1%26skind%3D%26sword%3D%26ob%3D> [retrieved on 20240219] *

Also Published As

Publication number Publication date
KR102569532B1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
KR102273950B1 (en) Cutibacterium acnes subsp. acnes strain and skin condition improving uses of thereof
WO2021060659A1 (en) Staphylococcus capitis st-1 strain, and use thereof for improving skin condition
WO2021060656A1 (en) Staphylococcus gallinarum st-4 strain, and use thereof for improving skin condition
WO2021060654A1 (en) Staphylococcus epidermidis strain st-6 and use thereof for improving condition of skin
KR102334455B1 (en) Corynebacterium macginleyi strain and skin condition improving uses of thereof
WO2024025173A1 (en) Cosmetic composition comprising staphylococcus sp. strain, streptococcus sp. strain, cutibacterium sp. strain, enhydrobacter sp. strain, and dna fragment mixture
KR102286075B1 (en) Staphylococcus lentus ST-2 strain and skin condition improving uses of thereof
KR102334454B1 (en) Corynebacterium tuberculostearicum strain and skin condition improving uses of thereof
KR102321536B1 (en) Corynebacterium amycolatum strain and skin condition improving uses of thereof
WO2021060652A1 (en) Staphylococcus haemolyticus strain st-8 and use thereof for improving condition of skin
WO2023243924A1 (en) Micrococcus terreus strain and use thereof for improving skin condition
WO2024005443A1 (en) Micrococcus flavus strain and use thereof for improving skin condition
WO2023018078A1 (en) Micrococcus antarcticus strain and skin condition improving use thereof
KR102334450B1 (en) Corynebacterium jeikeium strain and skin condition improving uses of thereof
KR102334457B1 (en) Microbacterium oleivorans strain and skin condition improving uses of thereof
KR102334449B1 (en) Corynebacterium accolens strain and skin condition improving uses of thereof
KR102336747B1 (en) Pantoea ananatis strain and skin condition improving uses of thereof
KR102334452B1 (en) Corynebacterium urealyticum strain and skin condition improving uses of thereof
KR102334451B1 (en) Corynebacterium afermentans strain and skin condition improving uses of thereof
KR102609655B1 (en) Streptococcus sobrinus strain and its use for improving skin conditions
KR102609656B1 (en) Staphylococcus hominis strain and its use for improving skin conditions
WO2021060653A1 (en) Staphylococcus sciuri st-7 strain, and use thereof for improving skin condition
WO2021060649A1 (en) Staphylococcus intermedius st-11 strain and use thereof for improving skin condition
WO2021060657A1 (en) Staphylococcus cohnii st-3 strain and use thereof for improving skin condition
WO2023018077A1 (en) Microccocus cohnii strain, and use thereof for improving condition of skin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23846832

Country of ref document: EP

Kind code of ref document: A1